

Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 13, 2005, 07:46:47 ; Search time 43 Seconds
(without alignments)

539.904 Million cell updates/sec

Title: US-09-263-689-4

Perfect score: 311

Sequence: 1 MAFSQSQAPYLSPAVPFGST.....LPTINRLEVGGDIQLTHVQT 311

Scoring table: OLAGO

Gapop 60.0 , Gapext 60.0

Searched: 513545 seqs, 74649064 residues

Word size : 0

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database :	Issued_Patents_AA.*
1:	/cggn2_6/proddata/1/iaa/5A_COMB.pep:*
2:	/cggn2_6/proddata/1/iaa/5B_COMB.pep:*
3:	/cggn2_6/proddata/1/iaa/6A_COMB.pep:*
4:	/cggn2_6/proddata/1/iaa/6B_COMB.pep:*
5:	/cggn2_6/proddata/1/iaa/8CTTUS_COMB.pep:*
6:	/cggn2_6/proddata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	311	100.0	311	3	US-09-946-914-4	Sequence 4, Appli
2	311	100.0	311	4	US-09-656-450-4	Sequence 4, Appli
3	163	52.4	355	4	US-09-126-102C-18	Sequence 18, Appli
4	163	52.4	378	4	US-09-854-133-439	Sequence 439, Appli
5	148	47.6	168	4	US-09-401-064-199	Sequence 199, Appli
6	148	47.6	301	4	US-09-159-033-4	Sequence 4, Appli
7	87	28.0	323	4	US-09-326-102C-19	Sequence 19, Appli
8	69	22.2	145	2	US-08-788-584-1	Sequence 1, Appli
9	69	22.2	149	2	US-08-788-584-3	Sequence 3, Appli
10	22	7.1	322	4	US-09-559-023-2	Sequence 2, Appli
11	20	6.4	145	2	US-08-788-584-5	Sequence 5, Appli
12	20	6.4	145	3	US-08-146-914-12	Sequence 12, Appli
13	20	6.4	145	4	US-09-656-450-12	Sequence 12, Appli
14	20	6.4	145	4	US-09-557-170A-3	Sequence 3, Appli
15	12	3.9	262	3	US-08-946-914-14	Sequence 14, Appli
16	12	3.9	262	4	US-09-656-450-14	Sequence 14, Appli
17	10	3.2	275	4	US-09-557-170A-35	Sequence 25, Appli
18	10	3.2	296	4	US-09-557-170A-27	Sequence 27, Appli
19	10	3.2	324	3	US-08-946-914-11	Sequence 11, Appli
20	10	3.2	324	4	US-09-655-450-11	Sequence 11, Appli
21	10	3.2	336	3	US-09-131-648-1	Sequence 1, Appli
22	9	2.9	422	4	US-09-270-567-42572	Sequence 42572, A
23	8	2.6	43	4	US-08-875-553D-43	Sequence 43, Appli
24	8	2.6	45	4	US-08-175-553D-41	Sequence 41, Appli
25	8	2.6	45	4	US-08-875-553D-42	Sequence 42, Appli
26	8	2.6	46	4	US-08-875-553D-40	Sequence 40, Appli
27	8	2.6	143	4	US-09-877-790-1	Sequence 1, Appli

ALIGMENTS

RESULT 1
US-09-946-914-4
; Sequence 4, Application US/08946914
; Patent No. 6027936

GENERAL INFORMATION:
 / APPLICANT: Ni, Jian
 / APPLICANT: Gentz, Reiner L.
 / APPLICANT: Ruben, Steven M.
 / TITLE OF INVENTION: Galexton 8, 9, 10 and 10SV
 / NUMBER OF SEQUENCES: 60
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Sterne, Kessler, Goldstein, & Fox P.L.L.C.
 / STREET: 1100 New York Ave., Suite 600
 / CITY: Washington
 / STATE: D.C.
 / COUNTRY: USA
 / ZIP: 20005-3934
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: FLOPPY disk
 / COMPUTER: IBM PC compatible
 / OPERATING SYSTEM: PC DOS/MS-DOS
 / SOFTWARE: PatentIn Release #1.0, Version #1.30
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/946,914
 / FILING DATE: Herewith
 / CLASSIFICATION: 530
 / PRIOR APPLICATION DATA:
 / APPLICATION NUMBER: US 60/028,093
 / FILING DATE: 09-OCT-1996
 / ATTORNEY/AGENT INFORMATION:
 / NAME: Steffe, Eric K.
 / REGISTRATION NUMBER: 36,688
 / REFERENCE/DOCKET NUMBER: 1488-0560001/EKS/SGW
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: 202-312-2600
 / TELEFAX: 202-371-2540
 / INFORMATION FOR SEQ ID NO. 4:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 311 amino acids
 / TYPE: amino acid
 / TOPOLOGY: linear
 / MOLECULE TYPE: protein
 / US-08-946-914-4

Query Match 100.0%; Score 311; DB 3; Length 311;
 Best Local Similarity 100.0%; Pred. No. 9.2e-300;
 Matches 311; Conservative 0; Missmatches 0; Indels 0; Gaps 0;

Qy 1 MAFSQQAPYLSPAVPFGSTIQGGLQDGLOITNCTVLSSSGTRAVNPOTGFSSNDIAF 60

Query Match 52.4%; Score 163; DB 4; Length 378;
 Best Local Similarity 100.0%; Pred. No. 4.2e-153; Mismatches 0; Indels 0; Gaps 0;
 Matches 163; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 4 LENGTH: 301 TYPE: PRT ORGANISM: Human US-09-559-023-4

Query Match 47.6%; Score 148; DB 4; Length 301;
 Best Local Similarity 100.0%; Pred. No. 2.4e-138; Mismatches 0; Indels 0; Gaps 0;
 Matches 148; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 5 LENGTH: 311 TYPE: PRT ORGANISM: Human US-09-401-064-199

Query Match 47.6%; Score 148; DB 4; Length 301;
 Best Local Similarity 100.0%; Pred. No. 2.4e-138; Mismatches 0; Indels 0; Gaps 0;
 Matches 148; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 6 LENGTH: 316 TYPE: PRT ORGANISM: Human US-09-401-064-199

Query Match 47.6%; Score 148; DB 4; Length 301;
 Best Local Similarity 100.0%; Pred. No. 2.4e-138; Mismatches 0; Indels 0; Gaps 0;
 Matches 148; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 7 LENGTH: 336 TYPE: PRT ORGANISM: Human US-09-401-064-199

RESULT 5
 US-09-401-064-199
 Sequence 1.99, Application US/09401064
 Patent No. 6623923
 GENERAL INFORMATION:
 APPLICANT: Xu, Jiangchun
 APPLICANT: Lodes, Michael J.
 APPLICANT: Sechrist, Heather
 APPLICANT: Benson, Darin R.
 APPLICANT: Meagher, Madeline Joy
 APPLICANT: Stoik, John A.
 APPLICANT: Wang, Tongcong
 TITLE OF INVENTION: COMPOUNDS FOR IMMUNOTHERAPY AND
 TITLE OF INVENTION: DIAGNOSTICS OF COLON CANCER AND METHODS FOR THEIR USE
 PCTA-1
 CURRENT APPLICATION NUMBER: US/09/401,064
 CURRENT FILING DATE: 1999-05-22
 NUMBER OF SEQ ID NOS: 371
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 199 LENGTH: 168
 TYPE: PRT
 ORGANISM: Homo sapien US-09-401-064-199

Query Match 47.6%; Score 148; DB 4; Length 168;
 Best Local Similarity 100.0%; Pred. No. 1.4e-138; Mismatches 0; Indels 0; Gaps 0;
 Matches 148; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 8 LENGTH: 168 TYPE: PRT ORGANISM: Homo sapien US-09-401-064-199

Query Match 47.6%; Score 148; DB 4; Length 168;
 Best Local Similarity 100.0%; Pred. No. 1.4e-138; Mismatches 0; Indels 0; Gaps 0;
 Matches 148; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 9 LENGTH: 168 TYPE: PRT ORGANISM: Homo sapien US-09-401-064-199

RESULT 6
 US-09-559-023-4
 Sequence 4, Application US/09559023
 Patent No. 6551795
 GENERAL INFORMATION:
 APPLICANT: Abramson, Ruth
 APPLICANT: Leib-Pinto, Edgar
 APPLICANT: Lipkowitz, Michael
 TITLE OF INVENTION: NUCLEIC ACID ENCODING URATE TRANSPORTER
 TITLE OF INVENTION: AND METHODS OF USE THEREOF
 FILE REFERENCE: 070165-0574
 CURRENT APPLICATION NUMBER: US/09/559,023
 CURRENT FILING DATE: 2000-04-27
 PRIOR APPLICATION NUMBER: US 09/221,898

Query Match 28.0%; Score 87; DB 4; Length 323;
 Best Local Similarity 100.0%; Pred. No. 6.6e-78; Mismatches 0; Indels 0; Gaps 0;
 Matches 87; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 10 LENGTH: 120 FILE REFERENCE: 070165-0574

Query Match 28.0%; Score 87; DB 4; Length 323;
 Best Local Similarity 100.0%; Pred. No. 6.6e-78; Mismatches 0; Indels 0; Gaps 0;
 Matches 87; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 11 LENGTH: 126 FILE REFERENCE: 070165-0574

Query Match 28.0%; Score 87; DB 4; Length 323;
 Best Local Similarity 100.0%; Pred. No. 6.6e-78; Mismatches 0; Indels 0; Gaps 0;
 Matches 87; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 12 LENGTH: 148 FILE REFERENCE: 070165-0574

Query Match 28.0%; Score 87; DB 4; Length 323;
 Best Local Similarity 100.0%; Pred. No. 6.6e-78; Mismatches 0; Indels 0; Gaps 0;
 Matches 87; Conservative 0; Software: FastSEQ for Windows Version 4.0
 SEQ ID NO 13 LENGTH: 148 FILE REFERENCE: 070165-0574

RESULT 8
 US-08-788-584-1

Sequence 1, Application US/08788584
 Patent No. 5837493
 GENERAL INFORMATION:
 APPLICANT: Hillman, Jennifer L.
 APPLICANT: Goli, Surya K.
 APPLICANT: Bandman, Oiga
 APPLICANT: Hawkins, Phillip R.
 APPLICANT: Petithory, Joanne R.
 TITLE OF INVENTION: NOVEL HUMAN GALECTINS
 NUMBER OF SEQUENCES: 5
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Incyte Pharmaceuticals, Inc.
 STREET: 3174 Porter Drive
 CITY: Palo Alto
 STATE: CA
 COUNTY: USA
 ZIP: 94304
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: FastSEQ for Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/788,584
 FILING DATE: Filed Herewith
 CLASSIFICATION: 436
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Billings, Lucy J.
 REGISTRATION NUMBER: 36,749
 REFERENCE/DOCKET NUMBER: PR-0192 US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 415-855-0555
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 145 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-788-584-1

RESULT 9
 Query Match 22.2%; Score 69; DB 2; Length 145;
 Best Local Similarity 100.0%; Pred. No. 2.1e-60;
 Matches 69; Conservative 0; Mismatches 0; Gaps 0;

Qy 243 WGSEERSLPRKMPFVRGQSSWVILCEAHLCKVAVDQHLEFYHRNLPTNRLEVGG 302
 Db 77 WGSEERSLPRKMPFVRGQSSWVILCEAHLCKVAVDQHLEFYHRNLPTNRLEVGG 136

Qy 303 DIOQLTHVQT 311
 Db 137 DIQLTHVQT 145

RESULT 9
 Query Match 7.1%; Score 22; DB 4; Length 322;
 Best Local Similarity 100.0%; Pred. No. 1.6e-13;
 Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Sequence 3, Application US/08788584
 Patent No. 5837493
 GENERAL INFORMATION:
 APPLICANT: Hillman, Jennifer L.
 APPLICANT: Goli, Surya K.
 APPLICANT: Bandman, Oiga
 APPLICANT: Hawkins, Phillip R.
 APPLICANT: Petithory, Joanne R.
 TITLE OF INVENTION: NOVEL HUMAN GALECTINS
 NUMBER OF SEQUENCES: 5
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Incyte Pharmaceuticals, Inc.
 STREET: 3174 Porter Drive
 CITY: Palo Alto

Qy 46 AVNFTQGFSGNIDIAFHNPRLPES 67
 Db 45 AVNFTQGFSGNIDIAFHNPRLPES 66

RESULT 11

US-08-788-584-5

/ Sequence 5, Application US/08788584

/ GENERAL INFORMATION:

/ APPLICANT: Hillman, Jennifer L.

/ APPLICANT: Goli, Surya K.

/ APPLICANT: Bandman, Olga

/ APPLICANT: Hawkins, Phillip R.

/ APPLICANT: Petithory, Joanne R.

/ TITLE OF INVENTION: NOVEL HUMAN GALECTINS

/ NUMBER OF SEQUENCES: 5

/ CORRESPONDENCE ADDRESS:

/ ADDRESSEE: Incyte Pharmaceuticals, Inc.

/ STREET: 3174 Porter Drive

/ CITY: Palo Alto

/ STATE: CA

/ COUNTRY: USA

/ ZIP: 94304

/ COMPUTER READABLE FORM:

/ MEDIUM TYPE: Diskette

/ COMPUTER: IBM Compatible

/ OPERATING SYSTEM: DOS

/ SOFTWARE: FastSEQ for Windows Version 2.0

/ CURRENT APPLICATION DATA:

/ APPLICATION NUMBER: US/08/788,584

/ FILING DATE: Filed Herewith

/ CLASSIFICATION: 436

/ PRIOR APPLICATION DATA:

/ APPLICATION NUMBER:

/ FILING DATE:

/ ATTORNEY/AGENT INFORMATION:

/ NAME: Billings, Lucy J.

/ REGISTRATION NUMBER: 36,749

/ REFERENCE/DOCKET NUMBER: PP-0192 US

/ TELECOMMUNICATION INFORMATION:

/ TELEPHONE: 415-855-0555

/ TELEFAX: 415-845-4166

/ INFORMATION FOR SEQ ID NO: 5:

/ SEQUENCE CHARACTERISTICS:

/ LENGTH: 145 amino acids

/ TYPE: amino acid

/ STRANDEDNESS: single

/ TOPOLOGY: linear

/ IMMEDIATE SOURCE:

/ CLONE: Genbank

/ US-08-788-584-5

/ Query Match

/ Best Local Similarity 100.0%; Pred. No. 7e-12;

/ Matches 0; Mismatches 0; Indels 0; Gaps 0;

/ Sequence 12, Application US/089469314

/ / Parent No. 6027916

/ / GENERAL INFORMATION:

/ / APPLICANT: Gentz, Reiner L.

/ / APPLICANT: Ruben, Steven M.

/ / TITLE OF INVENTION: Galectin 9 and 10 SV Polynucleotides

/ / CURRENT APPLICATION NUMBER: US/09/656,450

/ / CURRENT FILING DATE: 2000-09-06

/ / PRIOR APPLICATION NUMBER: US 09/263, 689

/ / PRIOR FILING DATE: 1999-03-05

/ / PRIOR APPLICATION NUMBER: US 08/946, 914

/ / PRIOR APPLICATION NUMBER: US 60/028, 093

/ / PRIOR FILING DATE: 1996-10-09

/ / NUMBER OF SEQ ID NOS: 60

/ / SOFTWARE: PatentIn version 3.0

/ / SEQ ID NO: 12

/ / LENGTH: 145

/ / TYPE: PRT

/ / ORGANISM: Rat

/ / TITLE OF INVENTION: Galectin 8, 9, 10 and 10SV

NUMBER OF SEQUENCES: 60
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Stern, Kassler, Goldstein, & Fox P.L.L.C.
 STREET: 1100 New York Ave., Suite 600
 CITY: Washington
 STATE: D.C.
 COUNTRY: USA
 ZIP: 20005-3934
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/946, 914
 FILING DATE: Herewith
 CLASSIFICATION: 530
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 60/028, 093
 ATTORNEY/AGENT INFORMATION:
 NAME: Steff, Eric K.
 REGISTRATION NUMBER: 36,688
 REFERENCE/DOCKET NUMBER: 1488.0560001/EKS/SGW
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-371-2500
 TELEFAX: 202-371-2500
 INFORMATION FOR SEQ ID NO: 12:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 145 amino acids
 TYPE: amino acid
 STRANDEDNESS: not relevant
 TOPOLOGY: linear
 MOLECULE TYPE: cDNA
 US-08-946-914-12

Query Match 6.4%; Score 20; DB 3; Length 145;
 Best Local Similarity 100.0%; Pred. No. 7e-12; Mismatches 0; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 220 IAFHLNPREFDENAVVRNTQI 239
 Db 54 IAFHLNPREFDENAVVRNTQI 73

RESULT 13
 US-09-656-450-12
 / Sequence 12, Application US/09656450
 / Patent No. 6468768
 / GENERAL INFORMATION:
 / APPLICANT: Ni, Jian
 / APPLICANT: Gentz, Reiner L.
 / APPLICANT: Ruben, Steven M.
 / TITLE OF INVENTION: Galectin 9 and 10 SV Polynucleotides
 / FILE REFERENCE: 1488.0560003
 / CURRENT APPLICATION NUMBER: US/09/656,450
 / CURRENT FILING DATE: 2000-09-06
 / PRIOR APPLICATION NUMBER: US 09/263, 689
 / PRIOR FILING DATE: 1999-03-05
 / PRIOR APPLICATION NUMBER: US 08/946, 914
 / PRIOR FILING DATE: 1997-10-09
 / PRIOR APPLICATION NUMBER: US 60/028, 093
 / PRIOR FILING DATE: 1996-10-09
 / NUMBER OF SEQ ID NOS: 60
 / SOFTWARE: PatentIn version 3.0
 / SEQ ID NO: 12
 / LENGTH: 145
 / TYPE: PRT
 / ORGANISM: Rat
 US-09-656-450-12

Query Match 6.4%; Score 20; DB 4; Length 145;
 Best Local Similarity 100.0%; Pred. No. 7e-12;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0; APPLICATION NUMBER: US 60/028,093
 FILING DATE: 09-OCT-1996
 ATTORNEY/AGENT INFORMATION:
 NAME: Steffe, Eric K.
 REGISTRATION NUMBER: 36,688
 REFERENCE/DOCKET NUMBER: 1488-0560001/EKS/SGW
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-371-2600
 TELEFAX: 202-371-2540
 INFORMATION FOR SEQ ID NO: 14:
 SUBSEQUENCE CHARACTERISTICS:
 LENGTH: 262 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-946-914-14

Query Match 3.9%; Score 12; DB 3; Length 262;
 Best Local Similarity 100.0%; Pred. No. 0.001; Mismatches 0; Indels 0; Gaps 0;
 Matches 12; Conservative 0; MisMatches 0;

Qy 55 GNDIAFHFNPRF 66
 ||||| | | | | | |
 Db 164 GNDIAFHFNPRF 175

Search completed: July 13, 2005, 07:47:39
 Job time : 44 secs

RESULT 14
 US-09-557-170A-3
 / Sequence 3, Application US/09557170A
 / PATENT NO. 6605639
 / GENERAL INFORMATION:
 / APPLICANT: Ni et al.
 / TITLE OF INVENTION: Galectin 11
 / FILE REFERENCE: PE35GP2
 / CURRENT APPLICATION NUMBER: US/09/557,170A
 / PRIOR FILING DATE: 2000-04-21
 / PRIOR APPLICATION NUMBER: 09/109,864
 / PRIOR FILING DATE: 1998-06-06
 / PRIOR APPLICATION NUMBER: 09/010,146
 / PRIOR FILING DATE: 1998-01-21
 / PRIOR APPLICATION NUMBER: 60/034,205
 / PRIOR FILING DATE: 1997-01-21
 / PRIOR APPLICATION NUMBER: 60/034,204
 / PRIOR FILING DATE: 1997-01-21
 / PRIOR APPLICATION NUMBER: 60/169,932
 / PRIOR FILING DATE: 1999-12-10
 / PRIOR APPLICATION NUMBER: 60/130,390
 / PRIOR FILING DATE: 1999-04-21
 / NUMBER OF SEQ ID NOS: 27
 / SOFTWARE: PatentIn Ver. 2.1
 / SEQ ID NO 3
 / LENGTH: 145
 / TYPE: PRT
 / ORGANISM: Homo sapiens

US-09-557-170A-3

Query Match 6.4%; Score 20; DB 4; Length 145;
 Best Local Similarity 100.0%; Pred. No. 7e-12; Mismatches 0; Indels 0; Gaps 0;

Qy 220 IAFHLNPRFDENAVVRNTQI 239
 Db 54 IAFHLNPRFDENAVVRNTQI 73

RESULT 15
 US-08-946-914-14
 / Sequence 14, Application US/08946914
 / Patent No. 6027916
 / GENERAL INFORMATION:
 / APPLICANT: Ni, Jian
 / APPLICANT: Gentz, Reiner L.
 / APPLICANT: Ruben, Steven M.
 / TITLE OF INVENTION: Galectin 8, 9, 10 and 10SV
 / NUMBER OF SEQUENCES: 60
 / CORRESPONDENCE ADDRESS:
 / ADDRESSEE: Steerne, Kessler, Goldstein, & Fox P.L.L.C.
 / STREET: 1100 New York Ave., Suite 600
 / CITY: Washington
 / STATE: D.C.
 / COUNTRY: USA
 / ZIP: 20005-3934
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / COMPUTER: IBM PC compatible
 / OPERATING SYSTEM: PC-DOS/MS-DOS
 / SOFTWARE: PatentIn Release #1.0, Version #1.30
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/946,914
 / FILING DATE: Herewith
 / CLASSIFICATION: 530
 / PRIOR APPLICATION DATA:

TELEPHONE: 202-371-2600
 TELEFAX: 202-371-2540
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 311 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-09-263-689-4

Query Match 100.0%; Score 311; DB 9; Length 311;
 Best Local Similarity 100.0%; Pred. No. 1.e-283;
 Matches 311; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAEFGSQAPYLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 60
 Db 1 HFNPRPEDGGVYVNTROGSWGLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 60
 Qy 1 MAEFGSQAPYLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 60
 Db 1 HFNPRPEDGGVYVNTROGSWGLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 60
 Qy 61 HFNPRPEDGGVYVNTROGSWGLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 120
 Db 61 HFNPRPEDGGVYVNTROGSWGLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 120
 Qy 121 QYFRVPFRVDITISVNGSVQLSYISFOTQTVHTVQSAQGMESTPAIPPMYPHPAYP 180
 Db 121 QYFRVPFRVDITISVNGSVQLSYISFOTQTVHTVQSAQGMESTPAIPPMYPHPAYP 180
 Qy 181 MPFTTILGGLYPSKSILLSGTVLPSAQDFHINICSGNHAFLHNPRDENAVRNTQID 240
 Db 181 MPFTTILGGLYPSKSILLSGTVLPSAQDFHINICSGNHAFLHNPRDENAVRNTQID 240
 Qy 241 NSMGSEERSLPKMPFVRGQSFSTWILCEAHCLKVAYDQHLPFYHRNLPTINRLEV 300
 Db 241 NSMGSEERSLPKMPFVRGQSFSTWILCEAHCLKVAYDQHLPFYHRNLPTINRLEV 300
 Qy 301 GDDIOLTHVQT 311
 Db 301 GDDIOLTHVQT 311

RESULT 3
 US-10-415-586-3
 ; Sequence 3, Application US/10415586
 ; Publication No US2004003346A1
 ; GENERAL INFORMATION:
 ; APPLICANT: YAMASHITA, Mitsumi
 ; APPLICANT: YAMAUCHI, Akira
 ; APPLICANT: KAGESHITA, Tohiko
 ; APPLICANT: NAKAMURA, Takanori
 ; APPLICANT: NISHI, No. US20040053346Alomu
 ; TITLE OF INVENTION: Predicting agent for a metastasis
 ; FILE REFERENCE: 2003-0572A/WNC/0132
 ; CURRENT APPLICATION NUMBER: US/10/415,586
 ; CURRENT FILING DATE: 2003-09-05
 ; PRIORITY NUMBER: PCT/JP01/09561
 ; PRIORITY NUMBER: JP 2000-335077
 ; PRIORITY NUMBER: US/10/415,586
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 3
 ; LENGTH: 311
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-415-586-3

Query Match 98.4%; Score 306; DB 15; Length 311;
 Best Local Similarity 100.0%; Pred. No. 5.4e-279;
 Matches 306; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 SQAPYLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAFHFNPR 65
 Db 6 SQAPYLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAFHFNPR 65
 Qy 66 PEDGGVYVNTROGSWGLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAFHFNPR 125
 Db 66 PEDGGVYVNTROGSWGLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAFHFNPR 125
 Qy 126 VPFRVDITISVNGSVQLSYISFOTQTVHTVQSAQGMESTPAIPPMYPHPAYMPFT 185
 Db 126 VPFRVDITISVNGSVQLSYISFOTQTVHTVQSAQGMESTPAIPPMYPHPAYMPFT 185
 Qy 186 TILOGLYPSKSILLSGTVLPSAQDFHINICSGNHAFLHNPRDENAVRNTQIDNSWS 245
 Db 186 TILOGLYPSKSILLSGTVLPSAQDFHINICSGNHAFLHNPRDENAVRNTQIDNSWS 245
 Qy 246 EERSLPKMPFVRGQSFSTWILCEAHCLKVAYDQHLPFYHRNLPTINRLEVGGDQ 305
 Db 246 EERSLPKMPFVRGQSFSTWILCEAHCLKVAYDQHLPFYHRNLPTINRLEVGGDQ 305

Query Match 100.0%; Score 311; DB 14; Length 311;
 Best Local Similarity 100.0%; Pred. No. 1.e-283;
 Matches 311; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAEFGSQAPYLSPAVPFSGTIGGLQIYTNGTVLSSSGTRFAVNQTGFSGNDIAF 60

RESULT 4
 Qy 306 LTHVQT 311
 Db 306 LTHVQT 311
 ; ORGANISM: Homo sapiens
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO: 141
 ; LENGTH: 323
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-024-298A-141

Query Match 52.4%; Score 163; DB 14; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTVHTVQSGPQMSTPAIPPMYPHPAYMPITTLGGLYPSKSILLSGTVPMSAQ 208
 Db 161 TQTVHTVQSGPQMSTPAIPPMYPHPAYMPITTLGGLYPSKSILLSGTVPMSAQ 220

Qy 209 RFHINLCSGNHIAFLNPRDENAVRNTQIDNSGSEERSLPRMPPFVRGQSFVWILC 268
 Db 221 RFHINLCSGNHIAFLNPRDENAVRNTQIDNSGSEERSLPRMPPFVRGQSFVWILC 280

Qy 269 EAHCILKVAVDQQLPEYYHLRLNLIPTINRLLEVGGDIQLTHVQT 311
 Db 281 EAHCILKVAVDQQLPEYYHLRLNLIPTINRLLEVGGDIQLTHVQT 323

SEQ ID NO: 2
 LENGTH: 323
 ; ORGANISM: Homo sapiens
 ; SOFTWARE: PatentIn Ver. 2.1
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-728-479-2

Query Match 52.4%; Score 163; DB 9; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTVHTVQSGPQMSTPAIPPMYPHPAYMPITTLGGLYPSKSILLSGTVPMSAQ 208
 Db 161 TQTVHTVQSGPQMSTPAIPPMYPHPAYMPITTLGGLYPSKSILLSGTVPMSAQ 220

Qy 209 RFHINLCSGNHIAFLNPRDENAVRNTQIDNSGSEERSLPRMPPFVRGQSFVWILC 268
 Db 221 RFHINLCSGNHIAFLNPRDENAVRNTQIDNSGSEERSLPRMPPFVRGQSFVWILC 280

Qy 269 EAHCILKVAVDQQLPEYYHLRLNLIPTINRLLEVGGDIQLTHVQT 311
 Db 281 EAHCILKVAVDQQLPEYYHLRLNLIPTINRLLEVGGDIQLTHVQT 323

RESULT 5
 US-10-024-298A-141
 ; Sequence 141, Application US/10024298A
 ; Publication No. US20030143540A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Akio MATSUDA
 ; APPLICANT: Goichi HONDA
 ; APPLICANT: Yukiko NAGANO
 ; APPLICANT: Shuji MURAMATSU
 ; TITLE OF INVENTION: NP-K B Activating Gene
 ; CURRENT APPLICATION NUMBER: US/10/024,298A
 ; CURRENT FILING DATE: 2003-04-08
 ; PRIOR APPLICATION NUMBER: 60/314,385
 ; PRIOR FILING DATE: 2001-08-24
 ; PRIOR APPLICATION NUMBER: 60/278,641
 ; PRIOR FILING DATE: 2001-03-26
 ; PRIOR APPLICATION NUMBER: 60/258,315
 ; PRIOR FILING DATE: 2000-12-28
 ; PRIOR APPLICATION NUMBER: JP254018/2001
 ; PRIOR FILING DATE: 2001-03-26
 ; PRIOR APPLICATION NUMBER: JP 2001-254018
 ; PRIOR FILING DATE: 2001-03-24
 ; PRIOR APPLICATION NUMBER: US 60/258,315
 ; PRIOR FILING DATE: 2000-12-28
 ; PRIOR APPLICATION NUMBER: US 60/278,640
 ; PRIOR FILING DATE: 2001-03-26
 ; PRIOR APPLICATION NUMBER: US 60/314,385
 ; NUMBER OF SEQ ID NOS: 182
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO: 141
 ; LENGTH: 323
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-10-024-211A-141

Query Match 52.4%; Score 163; DB 14; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTVHTVQSGPQMSTPAIPPMYPHPAYMPITTLGGLYPSKSILLSGTVPMSAQ 208
 Db 161 TQTVHTVQSGPQMSTPAIPPMYPHPAYMPITTLGGLYPSKSILLSGTVPMSAQ 220

Qy 209 RFHINLCSGNHIAFLNPRDENAVRNTQIDNSGSEERSLPRMPPFVRGQSFVWILC 268
 Db 221 RFHINLCSGNHIAFLNPRDENAVRNTQIDNSGSEERSLPRMPPFVRGQSFVWILC 280

Qy 269 EAHCILKVAVDQQLPEYYHLRLNLIPTINRLLEVGGDIQLTHVQT 311
 Db 281 EAHCILKVAVDQQLPEYYHLRLNLIPTINRLLEVGGDIQLTHVQT 323

RESULT 7
 US-10-415-586-2

Sequence 2, Application US/10415586
 GENERAL INFORMATION:
 APPLICANT: HIRASHIMA, Mitsuomi
 APPLICANT: YANAGI, Akira
 APPLICANT: KAGESHITA, Toshiro
 APPLICANT: NAKAMURA, Takanori
 APPLICANT: NISHI, No.
 TITLE OF INVENTION: Predicting agent for a metastasis
 FILE REFERENCE: 2003-057224/WMC/01322
 CURRENT APPLICATION NUMBER: US/10/415,586
 CURRENT FILING DATE: 2003-09-05
 PRIOR APPLICATION NUMBER: PCT/JP01/09561.
 PRIOR FILING DATE: 2001-10-31
 PRIOR APPLICATION NUMBER: JP 2000-3350077
 PRIOR FILING DATE: 2000-11-01
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 2
 LENGTH: 323
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-415-586-2

Query Match 52.4%; Score 163; DB 15; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-14; Mismatches 0; Indels 0; Gaps 0;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTIVHTVQSAPGMFSTAIPPMYPHAYNPFITLGLYPSSKILLSGTVLPSAQ 208
 Db 161 TQTIVHTVQSAPGMFSTAIPPMYPHAYNPFITLGLYPSSKILLSGTVLPSAQ 220
 Qy 209 RFHINLCSGNHTAFHLNPREFDENAVRNTOIDNSWGSERSLPRKMPFVRGOSFSWILC 268
 Db 221 RFHINLCSGNHTAFHLNPREFDENAVRNTOIDNSWGSERSLPRKMPFVRGOSFSWILC 280
 Qy 269 EAHCILKVAVDGQLFELYHRLRNLIPTINRLEVGDIOLTQVQT 311
 Db 281 EAHCILKVAVDGQLFELYHRLRNLIPTINRLEVGDIOLTQVQT 323

RESULT 8
 US-10-617-217A-141
 Sequence 141, Application US/10617217A
 GENERAL INFORMATION:
 APPLICANT: MATSUDA, Akio et al.
 TITLE OF INVENTION: NF-kB ACTIVATING GENE
 FILE REFERENCE: 1254-0229P
 CURRENT FILING DATE: 2003-07-11
 PRIOR APPLICATION NUMBER: JP 2000-402283
 PRIOR FILING DATE: 2000-12-28
 PRIOR APPLICATION NUMBER: JP 2001-088912
 PRIOR FILING DATE: 2001-03-26
 PRIOR APPLICATION NUMBER: JP 2001-254018
 PRIOR FILING DATE: 2001-08-24
 PRIOR APPLICATION NUMBER: US 60/258,315
 PRIOR FILING DATE: 2000-12-28
 PRIOR APPLICATION NUMBER: US 60/278,640
 PRIOR FILING DATE: 2001-03-26
 NUMBER OF SEQ ID NOS: 224
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 141
 LENGTH: 323
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-617-217A-141

Query Match 52.4%; Score 163; DB 16; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-14; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTIVHTVQSAPGMFSTAIPPMYPHAYNPFITLGLYPSSKILLSGTVLPSAQ 208
 Db 161 TQTIVHTVQSAPGMFSTAIPPMYPHAYNPFITLGLYPSSKILLSGTVLPSAQ 220
 Qy 209 RFHINLCSGNHTAFHLNPREFDENAVRNTOIDNSWGSERSLPRKMPFVRGOSFSWILC 268
 Db 221 RFHINLCSGNHTAFHLNPREFDENAVRNTOIDNSWGSERSLPRKMPFVRGOSFSWILC 280
 Qy 269 EAHCILKVAVDGQLFELYHRLRNLIPTINRLEVGDIOLTQVQT 311
 Db 281 EAHCILKVAVDGQLFELYHRLRNLIPTINRLEVGDIOLTQVQT 323

RESULT 9
 US-10-024-298A-141
 Sequence 141, Application US/10024298A
 Publication No. US20040214167A9
 GENERAL INFORMATION:
 APPLICANT: ASAHI KASEI KABUSHIKI KAISHA
 APPLICANT: AKIO MATSUDA
 APPLICANT: Goichi HONDA
 APPLICANT: Shuji MURAMATSU
 APPLICANT: Yukiko NAGANO
 TITLE OF INVENTION: NF-kB Activating Gene
 FILE REFERENCE: 1254-0191P
 CURRENT APPLICATION NUMBER: US/10/024,298A
 CURRENT FILING DATE: 2003-04-08
 PRIOR APPLICATION NUMBER: 60/314,385
 PRIOR FILING DATE: 2001-08-24
 PRIOR APPLICANT NUMBER: 60/278,641
 PRIOR FILING DATE: 2001-03-26
 PRIOR APPLICATION NUMBER: 60/258,315
 PRIOR FILING DATE: 2000-12-28
 PRIOR APPLICATION NUMBER: JP-54018/2001
 PRIOR FILING DATE: 2001-08-24
 PRIOR APPLICATION NUMBER: JP0088912/2001
 PRIOR FILING DATE: 2001-03-26
 PRIOR APPLICATION NUMBER: JP-022288/2000
 PRIOR FILING DATE: 2000-12-28
 NUMBER OF SEQ ID NOS: 182
 SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 141
 LENGTH: 323
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-024-298A-141

Query Match 52.4%; Score 163; DB 16; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-14; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTIVHTVQSAPGMFSTAIPPMYPHAYNPFITLGLYPSSKILLSGTVLPSAQ 208
 Db 161 TQTIVHTVQSAPGMFSTAIPPMYPHAYNPFITLGLYPSSKILLSGTVLPSAQ 220
 Qy 209 RFHINLCSGNHTAFHLNPREFDENAVRNTOIDNSWGSERSLPRKMPFVRGOSFSWILC 268
 Db 221 RFHINLCSGNHTAFHLNPREFDENAVRNTOIDNSWGSERSLPRKMPFVRGOSFSWILC 280
 Qy 269 EAHCILKVAVDGQLFELYHRLRNLIPTINRLEVGDIOLTQVQT 311
 Db 281 EAHCILKVAVDGQLFELYHRLRNLIPTINRLEVGDIOLTQVQT 323

RESULT 10
 US-10-376-133-18
 Sequence 18, Application US/10376133
 Publication No. US2003016596A1
 GENERAL INFORMATION:
 APPLICANT: EXELXIS, INC.
 TITLE OF INVENTION: LGALS AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE

Query Match 52.4%; Score 163; DB 15; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.4e-14;

FILE REFERENCE: EX03-014C
 CURRENT APPLICATION NUMBER: US/10/376,133
 CURRENT FILING DATE: 2003-02-28
 PRIORITY NUMBER: US 60/360,757
 PRIOR FILING DATE: 2002-03-01
 NUMBER OF SEQ ID NOS: 20
 SOFTWARE: Patent in version 3.2
 SEQ ID NO 18
 LENGTH: 355
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-376-133-18

Query Match Score 163; DB 14; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144; Indels 0; Gaps 0;
 Matches 163; Conservative 0; Mismatches 0; Delins 0; Gaps 0;

Qy 149 TQVIHTVQSAQGMESTPAIPPMYPHAYPMPFTTILGLYPSKSILLSGTVLPSAQ 208
 Db 193 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 252

Qy 209 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 268
 Db 253 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 312

Qy 269 EAHCLKVAVDGQHLFEYTHRLNLPTINRLEVGDIQLTHYQT 311
 Db 313 EAHCLKVAVDGQHLFEYTHRLNLPTINRLEVGDIQLTHYQT 355

Query Match Score 163; DB 15; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144; Indels 0; Gaps 0;
 Matches 163; Conservative 0; Mismatches 0; Delins 0; Gaps 0;

Qy 149 TQVIHTVQSAQGMESTPAIPPMYPHAYPMPFTTILGLYPSKSILLSGTVLPSAQ 208
 Db 193 TQVIHTVQSAQGMESTPAIPPMYPHAYPMPFTTILGLYPSKSILLSGTVLPSAQ 252

Qy 209 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 268
 Db 253 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 312

Qy 269 EAHCLKVAVDGQHLFEYTHRLNLPTINRLEVGDIQLTHYQT 311
 Db 313 EAHCLKVAVDGQHLFEYTHRLNLPTINRLEVGDIQLTHYQT 355

RESULT 1.3
 US-10-415-586-1
 Sequence 1, Application US/10415586
 Publication No. US20040053346A1
 GENERAL INFORMATION:
 APPLICANT: HIRASHIMA, Mitsuomi
 APPLICANT: YAMAUCHI, Akira
 APPLICANT: KAGESHIKA, Toshiro
 APPLICANT: NAKAMURA, Takanori
 APPLICANT: NISHI, No. US20040053346A0
 TITLE OF INVENTION: Predicting agent for a metastasis
 FILE REFERENCE: 2003-0572A/WMC/0332
 CURRENT FILING DATE: 2003-09-05
 PRIOR APPLICATION NUMBER: PCT/JP01/09561
 PRIOR FILING DATE: 2001-10-31
 PRIORITY NUMBER: JP 2000-33505077
 PRIOR FILING DATE: 2000-11-01
 NUMBER OF SEQ ID NOS: 9
 SOFTWARE: Patent in version 2.0
 SEQ ID NO 1
 LENGTH: 355
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-415-586-1

Query Match Score 163; DB 15; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144; Indels 0; Gaps 0;
 Matches 163; Conservative 0; Mismatches 0; Delins 0; Gaps 0;

Qy 149 TQVIHTVQSAQGMESTPAIPPMYPHAYPMPFTTILGLYPSKSILLSGTVLPSAQ 208
 Db 193 TQVIHTVQSAQGMESTPAIPPMYPHAYPMPFTTILGLYPSKSILLSGTVLPSAQ 252

Qy 209 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 268
 Db 253 RPHINLGSGNHTAFHINPRDENAVNTQIDNSWGSERSLPRKMPFVRCQSFSVWILC 312

Qy 269 EAHCLKVAVDGQHLFEYTHRLNLPTINRLEVGDIQLTHYQT 311
 Db 313 EAHCLKVAVDGQHLFEYTHRLNLPTINRLEVGDIQLTHYQT 355

RESULT 1.3
 US-10-633-035-6
 Sequence 6, Application US/10633035
 Publication No. US20040068104A1
 GENERAL INFORMATION:
 APPLICANT: Seisi Kato
 APPLICANT: Yamaguchi Kimura
 APPLICANT: Shingo Sekine
 APPLICANT: Kouju Kamata
 TITLE OF INVENTION: PROTEINS
 FILE REFERENCE: GIN-6707CPUS
 CURRENT APPLICATION NUMBER: US/10/633,035
 CURRENT FILING DATE: 2003-08-04
 PRIOR APPLICATION NUMBER: US/09/485,951
 PRIOR FILING DATE: 2000-02-17
 PRIOR APPLICATION NUMBER: 9-226468
 PRIOR FILING DATE: 1997-08-22
 PRIOR FILING DATE: 1998-08-19
 NUMBER OF SEQ ID NOS: 11
 SOFTWARE: Patent in version 2.0
 SEQ ID NO 6
 LENGTH: 355
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-633-035-6

Query Match 52.4%; Score 163; DB 15; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 APPLICANT: Mohamath, Radoh
 APPLICANT: Algate, Paul A.
 APPLICANT: Scerist, Heather
 APPLICANT: Indiris, Carol Joseph
 APPLICANT: Benson, Darin R.
 APPLICANT: Elliot, Mark
 APPLICANT: Mannion, Jane
 APPLICANT: Kalos, Michael D.
 TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
 TITLE OF INVENTION: THE THERAPY AND DIAGNOSIS OF LUNG CANCER
 CURRENT APPLICATION NUMBER: US/09/738,973
 CURRENT FILING DATE: 2000-12-14
 NUMBER OF SEQ ID NOS: 587
 SOFTWARE: FastSEQ for Windows Version 3.0
 SEQ ID NO 439
 LENGTH: 378
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-738-973-439

Query Match 52.4%; Score 163; DB 9; Length 378;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTIVHTVQSGMESTPAIPMMYPHAYPMPFITTLGGLYPSKSLLSGTVLPSAQ 208
 Db 193 TQTIVHTVQSGMESTPAIPMMYPHAYPMPFITTLGGLYPSKSLLSGTVLPSAQ 252
 Qy 209 RFHNLCSENHIAPHLNPFDENAVRNTQIDNSWGSEERSLPRKMPFVRGQFSWNLIC 268
 Db 253 RFHNLCSENHIAPHLNPFDENAVRNTQIDNSWGSEERSLPRKMPFVRGQFSWNLIC 312
 Qy 269 EAHCLKVADVGQLFEYTHRLNLPNTINLEVGDIOLTHVQT 311
 Db 313 EAHCLKVADVGQLFEYTHRLNLPNTINLEVGDIOLTHVQT 355

RESULT 14
 US-10-856-888-18
 Sequence 18, Application US/1056888
 GENERAL INFORMATION:
 Publication No. US20040233037A1
 APPLICANT: Blumenfeld, Marta
 APPLICANT: Bouquelaret, Lydie
 APPLICANT: Chumakov, Ily
 TITLE OF INVENTION: Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1 (PCTA-1)
 FILE REFERENCE: GEN_T112XCL
 CURRENT APPLICATION NUMBER: US/10/856,888
 CURRENT FILING DATE: 2004-05-27
 PRIOR APPLICATION NUMBER: US/09/326,402
 PRIOR FILING DATE: 1999-06-04
 PRIOR APPLICATION NUMBER: 60/188,187
 PRIOR FILING DATE: 1998-06-05
 PRIOR APPLICATION NUMBER: 60/102,324
 PRIOR FILING DATE: 1998-09-28
 NUMBER OF SEQ ID NOS: 22
 SOFTWARE: PatentIn version 3.1
 SEQ ID NO 18
 LENGTH: 355
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
 NAME/KEY: MISC_FEATURE
 LOCATION: (1)..(355)
 OTHER INFORMATION: amino acid sequence of gal9-1
 US-10-856-888-18

Query Match 52.4%; Score 163; DB 16; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 APPLICANT: Reed, Steven G.
 APPLICANT: Henderson, Robert A.
 APPLICANT: Lodes, Michael J.
 APPLICANT: Fling, Steven P.

Query Match 52.4%; Score 163; DB 16; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.6e-144;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 APPLICANT: Reed, Steven G.
 APPLICANT: Henderson, Robert A.
 APPLICANT: Lodes, Michael J.
 APPLICANT: Fling, Steven P.

Search completed: July 13, 2005, 08:34:36
 Job time : 1432 secs

Scoring table:							
OLIGO				Gapext 60.0 , Gapext 60.0			
Searched:				1612378 seqs, 512079187 residues			
Word size :	0	Total number of hits satisfying chosen parameters:	1612378	DB seq length:	0	Maximum DB seq length:	2000000000
Post-processing:	Listing first 45 summaries						
Database :	UniProt_03-* 1: uniprot_sprot: 2: uniprot_trembl: *						
Pred.	No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.						
SUMMARIES							
Result No.	Score	Query Match	Length	DB ID	Description		
1	311	100.0	311	2 Q8WYQ7	Q8WYQ7 homo sapien		
2	163	52.4	355	1 LEG9_HUMAN	Q00182 homo sapien		
3	41	13.2	356	2 QBDK12	Q6dk12 homo sapien		
4	22	7.1	322	2 Q6P7Q6	Q6P7Q6 rattus norv		
5	22	7.1	354	1 LEG9_RAT	P97810 rattus norv		
6	20	6.4	144	1 LEG5_RAT	P47967 rattus norv		
7	17	5.5	323	2 Q6QZP2	Q6qzp2 canis famili		
8	16	5.1	317	2 Q9XSM8	Q9xsm8 sus scrofa		
9	16	5.1	349	2 Q9XSM9	Q9xsm9 sus scrofa		
10	13	4.2	322	2 Q99L83	Q99l83 mus musculus		
11	13	4.2	353	1 LEG9_MOUSE	Q08573 mus musculus		
12	12	3.9	244	1 LEG3_CRLLO	P47953 cricetus		
13	12	3.9	261	1 LBG3_RAT	P08699 rattus norvegicus		
14	11	3.5	332	2 QBUW97	Q8uw97 xenopus laevis		
15	11	3.5	353	2 Q8PGR5	Q6Pgr5 xenopus laevis		
16	10	3.2	262	2 Q90713	Q90713 gallus gallus		
17	10	3.2	296	2 Q9NZ03	Q9nz03 homo sapiens		
18	10	3.2	308	2 Q7ZTB8	Q7ztb8 xenopus laevis		
19	10	3.2	324	1 LBG4_RAT	P38552 rattus norvegicus		
20	10	3.2	328	2 Q86GY9	Q86gy9 rhinoceros		
21	10	3.2	328	2 Q9TUB8	Q9tub8 orcto lagus		
22	10	3.2	332	2 QBGD9	Q8bgd9 gallus gallus		
23	10	3.2	336	1 LEGC_HUMAN	Q96dt0 homo sapiens		
24	9	2.9	162	1 QBNW59	Q8wn59 ovis aries		
25	9	2.9	265	2 Q94LY9	Q94ly9 oryza sativa		
26	9	2.9	503	2 Q9VPI6	Q9vp16 drosophila		
27	8	2.6	48	2 Q9QWA2	Q9qwa2 rattus sp.		
28	8	2.6	119	2 Q85FV3	Q85fv3 cyanidioschizae		
29	8	2.6	121	2 Q86FTYS	Q86ftys homosapiens		
30	8	2.6	122	2 Q8KA12	Q8ka12 chlorobium		
31	8	2.6	139	2 Q61357	Q61357 mus musculus		

ALIGNMENTS

RESULT 1		PRT; 311 AA.	
ID	Q8WYQ7	PRELIMINARY;	PRT;
AC	Q8WYQ7;		
DT	01-MAR-2002 (TREMBLrel. 20, Created)		
DT	01-MAR-2004 (TREMBLrel. 20, Last sequence update)		
DT	01-MAR-2004 (TREMBLrel. 26, Last annotation update)		
DB	Galectin-9.		
GN	Name-iGALu9;		
OS	Homo sapiens (Human).		
OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Cetarrhini; Hominidae; Homo.		
OC	NCBI_TaxID-9606;		
RN	[1]		
SEQUENCE FROM N.A.			
RA	Akiyama S;		
RL	Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.		
CC	-1 - SIMILARITY: Belongs to the Galectin (Galaptin/S-Lectin) family.		
DR	EMBL; AB040130; BAB3623_1; JOINED.		
DR	GO; GO:0005529; F:sugar binding; IEA.		
DR	PFam; PF003337; Gal-bind lectin; 2.		
DR	SMART; SM002766; GLECT; 2.		
DR	PROSITE; PS00309; GALAPTN; 2.		
KW	Galectin; Lectin.		
SEQUENCE	311 AA; 34690 MW; 3D00232F39DD776C CRC64;		
SQ	Query Match 100.0%; Score 311; DB 2; Length 311; Best Local Similarity 100.0%; Pred. No. 0; Matches 311; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1 MAFGSQAPYLSPATPFSGTLQGGIQLGLOLTIVNGTYLSSSGTRAVNFOTGSGNFDIAF 60 1 MAFGSQAPYLSPATPFSGTLQGGIQLGLOLTIVNGTYLSSSGTRAVNFOTGSGNFDIAF 60		
Db	1 MAFNPREDGGYVVCNTRONSWGPBERKTIMPFGKMPFDLCFL1QSSDFKVMVNGILFY 120 1 MAFNPREDGGYVVCNTRONSWGPBERKTIMPFGKMPFDLCFL1QSSDFKVMVNGILFY 120		
QY	61 HFNPREDGGYVVCNTRONSWGPBERKTIMPFGKMPFDLCFL1QSSDFKVMVNGILFY 120 61 HFNPREDGGYVVCNTRONSWGPBERKTIMPFGKMPFDLCFL1QSSDFKVMVNGILFY 120		
Db	61 HFNPREDGGYVVCNTRONSWGPBERKTIMPFGKMPFDLCFL1QSSDFKVMVNGILFY 120 61 HFNPREDGGYVVCNTRONSWGPBERKTIMPFGKMPFDLCFL1QSSDFKVMVNGILFY 120		
QY	61 QYFHRVPFHRYDTISVGSVQLSYLSFQTQIVHVTQSAQPMFSTPAIPPMYHPAYP 180 121 QYFHRVPFHRYDTISVGSVQLSYLSFQTQIVHVTQSAQPMFSTPAIPPMYHPAYP 180		
Db	121 QYFHRVPFHRYDTISVGSVQLSYLSFQTQIVHVTQSAQPMFSTPAIPPMYHPAYP 180 121 QYFHRVPFHRYDTISVGSVQLSYLSFQTQIVHVTQSAQPMFSTPAIPPMYHPAYP 180		
QY	181 MPFTITLGGLYPSKTSILISGTVLQAORTHINLQAFHLNPRFDEAVVNTQID 240 181 MPFTITLGGLYPSKTSILISGTVLQAORTHINLQAFHLNPRFDEAVVNTQID 240		
Db	181 MPFTITLGGLYPSKTSILISGTVLQAORTHINLQAFHLNPRFDEAVVNTQID 240 181 MPFTITLGGLYPSKTSILISGTVLQAORTHINLQAFHLNPRFDEAVVNTQID 240		
QY	241 NSWGSEERSLPRKMPFVRGQSFSWVILCEAHCLKVADGQLFEYHRLNLPTINRLEV 300 241 NSWGSEERSLPRKMPFVRGQSFSWVILCEAHCLKVADGQLFEYHRLNLPTINRLEV 300		
Db	241 NSWGSEERSLPRKMPFVRGQSFSWVILCEAHCLKVADGQLFEYHRLNLPTINRLEV 300 241 NSWGSEERSLPRKMPFVRGQSFSWVILCEAHCLKVADGQLFEYHRLNLPTINRLEV 300		
QY	301 GGDIQTHYQT 311 301 GGDIQTHYQT 311		

Db 301 GGDIQIQLTHVQT 311

	RESULT 2	
ID	LEG9 HUMAN STANDARD; PRT; 355 AA.	
AC	000182; O14532; Q9NQ58;	
CC	35 . Created)	
DT	01-NOV-1997 (Rel. 36 , Last sequence update)	
DT	15-JUL-1998 (Rel. 36 , Last sequence update)	
DT	25-JAN-2005 (Rel. 46 , Last annotation update)	
DE	Galectin-9 (HOM-HD-21) (Ecalectin).	
GN	Name=IGALS9;	
OS	Homo sapiens (Human).	
OC	Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi; OC	
NCB_TaxID=9606;	Metazoa; Primates; Catarrhini; Homiidae; Homo. OC	
OX		
RP	SEQUENCE FROM N.A. (ISOFORM SHORT).	
RC	TISSUE=Spleen; PubMed=101074/jbc.272.10.6416;	
RX	PubMed=9045665; DOI=10.1074/jbc.272.10.6416;	
RA	Tuerreci O , Schmitt H ., Fadie N , Pfreundschuh M ., Sahin U .;	
RT	"Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease.";	
RT	J. Biol. Chem. 272:6416-6422(1997).	
[2]		
RN	SEQUENCE FROM N.A. (ISOFORM LONG).	
RC	TISSUE=Gastric carcinoma;	
RA	Kato S ; Submitted (SEP-1997) to the EMBL/GenBank/DBJ databases.	
RN	[3]	
RP	SEQUENCE FROM N.A. (ISOFORM SHORT).	
RX	SequenceID=98307337; PubMed=9642261; DOI=10.1074/jbc.273.27.16976;	
RA	Marumoto R ., Matsumoto H ., Seki M ., Kata M ., Asano Y ., Kanegasaki S .,	
RA	Stevens R.L., Hirashima M .;	
RT	"Human galectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes.";	
RL	J. Biol. Chem. 273:16976-16984(1998).	
[4]		
RP	SEQUENCE FROM N.A. (ISOFORMS LONG AND SHORT).	
RA	Akiyama S ; "Homo sapiens Galectin-9 (LGALS9) / ecalectin gene, exon 2 through 11";	
RT	Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.	
[5]		
RP	SEQUENCE FROM N.A. (ISOFORM LONG).	
RA	Grassl J ., Spitzzenberger P ., Schroeder H.B .;	
RT	"Genomic organization of the human Galectin-9 gene.";	
RL	Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.	
CC	-!- FUNCTION: Binds lactosides. May play a role in thymocyte-epithelial interactions relevant to the bioactivity of the thymus. The short isoform acts as an eosinophil chemoattractant.	
CC	-!- ALTERNATIVE PRODUCTS:	
CC	Event=Alternative splicing; Named isoforms=2;	
CC	Comment=Additional isoforms seem to exist;	
CC	Name=Long;	
CC	IsId=000182-1; Sequence=Displayed;	
CC	Name=Short;	
CC	IsId=000182-2; Sequence=vSP_003096;	
CC	-!- TISSUES: Overexpressed in Hodgkin's disease tissue.	
CC	-!- DOMAIN: Contains two homologous but distinct carbohydrate-binding domains.	
CC	-!- SIMILARITY: Belongs to the galectin (galaptin/S-lectin) family.	
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).	
CC	EMBL; Z49107; CAA88922.1; -	
DR	EMBL; AB006782; BAA22166.1; -.	
DR	EMBL; AB005894; BAA3154.2.1; -.	
DR	EMBL; AB0040130; BAA83125.1; - JOINED.	
DR	EMBL; AB040129; BAB8325.1; JOINED.	
DR	EMBL; AB040130; BAB8324.1; - JOINED.	
DR	EMBL; AJ288083; CAB93851.1; - JOINED.	
DR	EMBL; AJ288084; CAB93851.1; JOINED.	
DR	EMBL; AJ288085; CAB93851.1; JOINED.	
DR	EMBL; AJ288087; CAB93851.1; JOINED.	
DR	EMBL; AJ288088; CAB93851.1; JOINED.	
DR	EMBL; AJ288089; CAB93851.1; JOINED.	
DR	EMBL; AU17931; IAKK.	
DR	GeneW; HGNC:6570; LGALS9.	
DR	MIM; 601879; -.	
DR	GO; GO:0005534; F:galactose binding; TAS.	
DR	InterPro; IPR008985; ConA-like_lec_g1.	
DR	Pfam; PF00337; Gal-bind_lectin.	
DR	PROSITE; PS00309; GALAPTIN_2.	
KW	Alternative splicing; Galectin; Lectin; Repeat.	
FT	DOMAIN 1 148 Galaptin 1.	
FT	DOMAIN 1 149 Galaptin 1.	
FT	SITE 205 Linker.	
FT	SITE 207 Galaptin 2.	
FT	SITE 82 Beta-galactoside binding 1 (By similarity).	
FT	SITE 88 Beta-galactoside binding 2 (By similarity).	
FT	SITE 287 Missing (in isoform Short).	
FT	VARSPLIC 149 /FTID=VSP_003096.	
FT	CONFLICT 5 5 G > S (in Ref. 5).	
FT	CONFLICT 48 48 NGS > D (in Ref. 5).	
FT	CONFLICT 79 81 KGR (in Ref. 5).	
FT	CONFLICT 88 88 K > R (in Ref. 1).	
FT	CONFLICT 89 89 T > M (in Ref. 5).	
FT	CONFLICT 135 135 S > P (in Ref. 1).	
FT	CONFLICT 270 270 P > L (in Ref. 1).	
FT	CONFLICT 313 313 E > G (in Ref. 1).	
FT	CONFLICT 326 326 L > V (in Ref. 5).	
FT	CONFLICT 341 341 R > K (in Ref. 5).	
SQ	SEQUENCE 3955 AA; 4748C22FCAPAF536A CRC64;	
	Query Match Score 52.4%; Length 355;	
	Best Local Similarity 100.0%; Pred. No. 1.7e-162;	
	Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	149 TQTVIHTYOSAPGMFSTPAIPPMYPPAYPMPFTITLGGLYPSKSILLSGTVPSSAQ 208	
Db	193 TQTVIHTYOSAPGMFSTPAIPPMYPPAYPMPFTITLGGLYPSKSILLSGTVPSSAQ 252	
QY	209 RFHINLCSENHIAFLNPREFDENAVRNTQIDNSWGEERSLPRKMPYRGQSFSWVILC 268	
Db	253 RFHINLCSENHIAFLNPREFDENAVRNTQIDNSWGEERSLPRKMPYRGQSFSWVILC 312	
QY	269 EAHCILKVADGQHFEYTHRLNLPTRNLPTIRLEVGDIQLTHVQT 311	
Db	313 EAHCILKVADGQHFEYTHRLNLPTRNLPTIRLEVGDIQLTHVQT 355	
	RESULT 3	
ID	Q6DK12 PRELIMINARY;	
AC	Q6DK12;	
DT	25-OCT-2004 (TREMBLrel. 28, Created)	
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)	
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)	
DE	Hypothetical protein.	
OS	Hom sapiens (Human).	
OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
OC	NCBI_TaxID=9606;	

- [1] SEQUENCE FROM N.A.
RN RP SEQUENCE=Pancreas;
RC TISSUE=Pancreas;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strasbourg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schueler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shemesh C.M., Schueler G.D.,
RA Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McIwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S.A., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Heitton E., Kettman J.A., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shewchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Butterfield Y.S.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Schein J.B.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnarch A., Schein J.B.,
RA Jones S.J., Marra M.A.; "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
[2]
RN SEQUENCE FROM N.A.
RP SEQUENCE FROM N.A.
RC TISSUE=Pituitary gland;
RA Strasbourg R.; Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
RL -I- SIMILARITY: Belongs to the galectin (galaptin/S-lectin) family.
CC DR EMBL: BC061566; AAH015661; -.
DR HSSP: P17931; 1A3K.
DR GO: GO:0005529; F:sugar binding; IBA.
DR InterPro: IPR008985; ConA-like_lec_g1.
DR Pfam: PF00337; Gal-bind lectin; 2.
DR SMART: SM00276; GLBCT; 2.
DR PROSITE: PS00309; GALAPTN; 2.
DR KW Lectin; Lectin.
SQ SEQUENCE 322 AA; 36341 MW; CDD41A6FD1BA9DD CRC64;
- [1] SEQUENCE FROM N.A.
RN RP SEQUENCE=Pancreas;
RC TISSUE=Pancreas;
RX MEDLINE=737889; PubMed=104 to the EMBL/GenBank/DBJ databases.
CC -I- SIMILARITY: Belongs to the galectin (galaptin/S-lectin) family.
DR EMBL: BC073889; AAH73889; 1.; GO: GO:0005529; F:sugar binding; IBA.
DR InterPro: IPR008985; ConA-like_lec_g1.
DR Pfam: PF00337; Gal-bind lectin; 2.
DR SMART: SM00276; GLBCT; 2.
DR PROSITE: PS00309; GALAPTN; 2.
KW Lectin; Hypothetical protein; Lectin.
SQ SEQUENCE 356 AA; 39633 MW; 933AD3A82B84784C CRC64;
- RESULT 5
Query Match 13.2%; Score 41; DB 2; Length 356;
Best Local Similarity 100.0%; Pred. No. 4.7e-34;
Matches 41; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Gaps 0;
- QY 241 NSWGSEERSLPRKMPYRGQSFSVWILCEAHCLKYAVDGQH 281
Db 286 NSWGSEERSLPRKMPYRGQSFSVWILCEAHCLKYAVDGQH 326
- OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Buteraria; Rodentia; Muridae; Murinae; Rattus.
OC NCBI_TaxID=10116;
RN [1]
RN SEQUENCE FROM N.A. (ISOFORM SHORT).
RN MEDLINE=97150759; PubMed=8995305; DOI=10.1074/jbc.272.1.617;
RA Leah-Pinto B.; Tao W.; Rapaport J.; Richardson M.; Knorr B.A.,
RA STRAIN=Sprague-Dawley; TISSUE=Kidney, and Small intestine;
RX MEDLINE=97190351; PubMed=9038233; DOI=10.1074/jbc.272.9.6078;
RA Wada J.; Kanwar Y.S.;
RT "Identification and characterization of galectin-9, a novel beta-
galactoside-binding mammalian lectin.";
RN [2]
RN SEQUENCE FROM N.A. (ISOFORM SHORT).
RC STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strasbourg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schueler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shemesh C.M., Schueler G.D.,
RA Altschul S.P., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA similarity). May provide the molecular basis for urate flux across

cell membranes, allowing urate that is formed during purine metabolism to efflux from cells and serving as an electrogenic transporter that plays an important role in renal and gastrointestinal urate excretion. Highly selective to the anion urate.

-!- SUBCELLULAR LOCATION: Cytoplasmic. May also be secreted by a non-classical secretory pathway (By similarity).

-!- ALTERNATIVE PRODUCTS:

CC Event=Alternative splicing; Named isoforms=2;

Comment=Additional isoforms seem to exist;

CC Name=Long; Sequence=Displayed;

CC IsoId=p97840-1; Sequence=Displayed;

CC Name=Short;

CC IsoId=p97840-2; Sequence=VSP 001098;

CC -!- TISSUE SPECIFICITY: The long form is expressed exclusively in the small intestine. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial domains requires a license agreement (See <http://www.isb-sib.ch/announce> or send an email to license@isb-sib.ch).

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - DR EMBL; US9462; AAB51192.1; -.

CC PROSITE: PS00337; Gal-bind Lectin; Lectin.

CC RGD: 3005; Igals5; InterPro; IPR008995; ConA-like_lec_g1; Pfam; PF00337; Gal-bind Lectin; Lectin.

CC DR EMBL; U72741; AAB8592.1; -.

CC DR EMBL; U7958; AAB8591.1; -.

CC DR HSSP; P17931; IAJ3C.

CC DR RGD; 3005; Igals9; InterPro; IPR001019; Galactin; PROSITE; PS003109; GALACTIN; 2.

CC DR KW Alternative splicing; Galactin; Ion transport; Lectin; Repeat DOMAIN 1 147 Galactin 1.

FT DOMAIN 148 205 Linker.

FT DOMAIN 206 354 Galactin 2.

FT SITE 81 87 Beta-galactoside binding 1 (By similarity)

FT SITE 286 292 Beta-galactoside binding 2 (By similarity).

FT VARSPLIC 148 179 Missing (in isoform Short).

SQ SEQUENCE 354 AA; 39946 MN; /PRID=VSP_003098; /PRT=6574F96B2EAFF37C CRC64;

Query Match 7.1%; Score 22; DB 1; Length 354;

Best Local Similarity 100.0%; Prod. No. 4.7e-14; Mismatches 0; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 46 AVNQTGFSGNDIAFHFNPRFE 67

Db 45 AVNQTGFSGNDIAFHFNPRFE 66

RESULT 6

LEGS_RAT STANDARD; PRT; 144 AA.

ID LEGS_RAT: P41967; DT 01-FEB-1996 (Rel. 33, Created) DT 25-JAN-2005 (Rel. 46, Last annotation update) DE Galactin-5 (RL-18).

GN Name=Lgals5;

OS Rattus norvegicus (Rat).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

NCBI_TaxID=9615;

RN [1]

RP SEQUENCE FROM N.A.

RA Bannasch D.L., Ryan J.R., Bannasch M.J., Schable R.H., Breen M., Lang G.; RT "Exclusion of galectin 9 as a candidate gene for hyperuricosuria in the Dalmatian dog"; RL Anim. Genet. 35:26-32 (2004). CC -!- SIMILARITY: Belongs to the galectin (Galaptin/S-lectin) family.

DR EMBL; AY521549; AAS80311.1; -.

DR HSSP; P17931; IAJ3K.

GO; GO:0005529; F:sugar binding; IEA.

DR InterPro; IPR008985; ConA-like_lec_g1.

DR InterPro; IPR01019; Galactin.

PFam; PF00337; Gal-bind Lectin; 2.

DR	InterPro; IPR01079; Galectin.		
DR	Pfam; PF00337; Gal-bind lectin;	2.	
DR	SMART; SM00276; GLECT;	2.	
DR	PROSITE; PS00309; GALAPTIN;	2.	
KW	Galectin; Lectin.		
SQ	SEQUENCE 322 AA; 36545 MW; 032D77400737562E CRC64;		
Query Match	Best Local Similarity 100.0%; Pred. No. 0.0013;	Length 322;	
Matches 13;	Conservative 0; Mismatches 0;	Indels 0;	Gaps 0;
Ov	55 GNDIAFHENPREFE 67		
Db	54 GNDIAFHENPREFE 66		
RESULT 11			
ID LEG9_MOUSE STANDARD; PRT; 353 AA.			
AC 008573; 008572;			
DT 01-NOV-1997 (Rel. 35, Created)			
DT 01-NOV-1997 (Rel. 35, Last sequence update)			
DT 25-JAN-2005 (Rel. 46, Last annotation update)			
DT 25-JAN-2005 (Rel. 46, Last)			
DS Galactin-9.			
GN Name=Igal89;			
OS Mus musculus (Mouse).			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
OX NCBI_TaxID=10090;			
RN [1]			
RP SEQUENCE FROM N.A.			
RC STRAIN=CD-1; TISSUE=Kidney, and Small intestine;			
RX MEDLINE=97190351; PubMed=9038233; DOI=10.1074/jbc.272.9.6078;			
RA Wada J.; Kanwar Y.S.;			
RT "Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin.";			
RT J. Biol. Chem. 272:6078-6086 (1997).			
[2]			
RP CHARACTERIZATION			
RX MEDLINE=97298141; PubMed=9153289;			
RA Wada J.; Ota K.; Kumar A.; Wallner E.I.; Kanwar Y.S.;			
RT "Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin.,"			
RT J. Clin. Invest. 99:2452-2461 (1997).			
-I- FUNCTION: Binds galactosides. May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus.			
-I- SUBCELLULAR LOCATION: Cytoplasmic. May also be secreted by a non-classical secretory pathway.			
-I- ALTERNATIVE PRODUCTS:			
CC Event=Alternative splicing; Named isoforms=2;			
CC Comment=Additional isoforms seem to exist;			
CC Name=Long;			
CC IsoId=008573-1; Sequence=Displayed;			
CC Name=Short;			
CC IsoId=008573-2; Sequence=VSP_003097;			
CC TISSUE SPECIFICITY: Accentuated expression in liver and thymus of embryo, detected in embryonic heart, brain, lung, liver, and kidney. Highly expressed in adult thymus, small intestine, and liver, and to a lesser extent in lung, kidney, spleen, cardiac, skeletal muscle. Barely detectable in brain and reticulocyte.			
CC The long form is expressed exclusively in the small intestine.			
CC -I- DEVELOPMENTAL STAGE: The expression increased with successive stages of embryonic development.			
CC -I- DOMAIN: Contains two homologous but distinct carbohydrate-binding domains.			
CC -I- SIMILARITY: Belongs to the galectin (Galaptin/S-lectin) family.			
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/ or send an email to license@sb-sib.ch).			
CC EMBL; U55061; AAB51190; 1;			
CC EMBL; U55060; AAB51189; 1;			
CC HSSP; P17931; 1A3K.			
CC MGI; MGI-10946; Igals9.			
CC InterPro; IPR00898; ConA-like_lec_g1.			
CC InterPro; IPR01079; Galectin.			
CC Pfam; PF00337; Gal-bind lectin.			
CC PROSITE; PS00309; GALAPTIN; 2.			
CC PROSITE; PS00367; GALAPTIN; 2.			
CC PROSITE; PS00377; Gal-bind lectin.			
CC PROSITE; PS00378; GALAPTIN; 1.			
CC PROSITE; PS00379; GALAPTIN; 1.			
CC PROSITE; PS00380; GALAPTIN; 1.			
CC PROSITE; PS00381; GALAPTIN; 1.			
CC PROSITE; PS00382; GALAPTIN; 1.			
CC PROSITE; PS00383; GALAPTIN; 1.			
CC PROSITE; PS00384; GALAPTIN; 1.			
CC PROSITE; PS00385; GALAPTIN; 1.			
CC PROSITE; PS00386; GALAPTIN; 1.			
CC PROSITE; PS00387; GALAPTIN; 1.			
CC PROSITE; PS00388; GALAPTIN; 1.			
CC PROSITE; PS00389; GALAPTIN; 1.			
CC PROSITE; PS00390; GALAPTIN; 1.			
CC PROSITE; PS00391; GALAPTIN; 1.			
CC PROSITE; PS00392; GALAPTIN; 1.			
CC PROSITE; PS00393; GALAPTIN; 1.			
CC PROSITE; PS00394; GALAPTIN; 1.			
CC PROSITE; PS00395; GALAPTIN; 1.			
CC PROSITE; PS00396; GALAPTIN; 1.			
CC PROSITE; PS00397; GALAPTIN; 1.			
CC PROSITE; PS00398; GALAPTIN; 1.			
CC PROSITE; PS00399; GALAPTIN; 1.			
CC PROSITE; PS00400; GALAPTIN; 1.			
CC PROSITE; PS00401; GALAPTIN; 1.			
CC PROSITE; PS00402; GALAPTIN; 1.			
CC PROSITE; PS00403; GALAPTIN; 1.			
CC PROSITE; PS00404; GALAPTIN; 1.			
CC PROSITE; PS00405; GALAPTIN; 1.			
CC PROSITE; PS00406; GALAPTIN; 1.			
CC PROSITE; PS00407; GALAPTIN; 1.			
CC PROSITE; PS00408; GALAPTIN; 1.			
CC PROSITE; PS00409; GALAPTIN; 1.			
CC PROSITE; PS00410; GALAPTIN; 1.			
CC PROSITE; PS00411; GALAPTIN; 1.			
CC PROSITE; PS00412; GALAPTIN; 1.			
CC PROSITE; PS00413; GALAPTIN; 1.			
CC PROSITE; PS00414; GALAPTIN; 1.			
CC PROSITE; PS00415; GALAPTIN; 1.			
CC PROSITE; PS00416; GALAPTIN; 1.			
CC PROSITE; PS00417; GALAPTIN; 1.			
CC PROSITE; PS00418; GALAPTIN; 1.			
CC PROSITE; PS00419; GALAPTIN; 1.			
CC PROSITE; PS00420; GALAPTIN; 1.			
CC PROSITE; PS00421; GALAPTIN; 1.			
CC PROSITE; PS00422; GALAPTIN; 1.			
CC PROSITE; PS00423; GALAPTIN; 1.			
CC PROSITE; PS00424; GALAPTIN; 1.			
CC PROSITE; PS00425; GALAPTIN; 1.			
CC PROSITE; PS00426; GALAPTIN; 1.			
CC PROSITE; PS00427; GALAPTIN; 1.			
CC PROSITE; PS00428; GALAPTIN; 1.			
CC PROSITE; PS00429; GALAPTIN; 1.			
CC PROSITE; PS00430; GALAPTIN; 1.			
CC PROSITE; PS00431; GALAPTIN; 1.			
CC PROSITE; PS00432; GALAPTIN; 1.			
CC PROSITE; PS00433; GALAPTIN; 1.			
CC PROSITE; PS00434; GALAPTIN; 1.			
CC PROSITE; PS00435; GALAPTIN; 1.			
CC PROSITE; PS00436; GALAPTIN; 1.			
CC PROSITE; PS00437; GALAPTIN; 1.			
CC PROSITE; PS00438; GALAPTIN; 1.			
CC PROSITE; PS00439; GALAPTIN; 1.			
CC PROSITE; PS00440; GALAPTIN; 1.			
CC PROSITE; PS00441; GALAPTIN; 1.			
CC PROSITE; PS00442; GALAPTIN; 1.			
CC PROSITE; PS00443; GALAPTIN; 1.			
CC PROSITE; PS00444; GALAPTIN; 1.			
CC PROSITE; PS00445; GALAPTIN; 1.			
CC PROSITE; PS00446; GALAPTIN; 1.			
CC PROSITE; PS00447; GALAPTIN; 1.			
CC PROSITE; PS00448; GALAPTIN; 1.			
CC PROSITE; PS00449; GALAPTIN; 1.			
CC PROSITE; PS00450; GALAPTIN; 1.			
CC PROSITE; PS00451; GALAPTIN; 1.			
CC PROSITE; PS00452; GALAPTIN; 1.			
CC PROSITE; PS00453; GALAPTIN; 1.			
CC PROSITE; PS00454; GALAPTIN; 1.			
CC PROSITE; PS00455; GALAPTIN; 1.			
CC PROSITE; PS00456; GALAPTIN; 1.			
CC PROSITE; PS00457; GALAPTIN; 1.			
CC PROSITE; PS00458; GALAPTIN; 1.			
CC PROSITE; PS00459; GALAPTIN; 1.			
CC PROSITE; PS00460; GALAPTIN; 1.			
CC PROSITE; PS00461; GALAPTIN; 1.			
CC PROSITE; PS00462; GALAPTIN; 1.			
CC PROSITE; PS00463; GALAPTIN; 1.			
CC PROSITE; PS00464; GALAPTIN; 1.			
CC PROSITE; PS00465; GALAPTIN; 1.			
CC PROSITE; PS00466; GALAPTIN; 1.			
CC PROSITE; PS00467; GALAPTIN; 1.			
CC PROSITE; PS00468; GALAPTIN; 1.			
CC PROSITE; PS00469; GALAPTIN; 1.			
CC PROSITE; PS00470; GALAPTIN; 1.			
CC PROSITE; PS00471; GALAPTIN; 1.			
CC PROSITE; PS00472; GALAPTIN; 1.			
CC PROSITE; PS00473; GALAPTIN; 1.			
CC PROSITE; PS00474; GALAPTIN; 1.			
CC PROSITE; PS00475; GALAPTIN; 1.			
CC PROSITE; PS00476; GALAPTIN; 1.			
CC PROSITE; PS00477; GALAPTIN; 1.			
CC PROSITE; PS00478; GALAPTIN; 1.			
CC PROSITE; PS00479; GALAPTIN; 1.			
CC PROSITE; PS00480; GALAPTIN; 1.			
CC PROSITE; PS00481; GALAPTIN; 1.			
CC PROSITE; PS00482; GALAPTIN; 1.			
CC PROSITE; PS00483; GALAPTIN; 1.			
CC PROSITE; PS00484; GALAPTIN; 1.			
CC PROSITE; PS00485; GALAPTIN; 1.			
CC PROSITE; PS00486; GALAPTIN; 1.			
CC PROSITE; PS00487; GALAPTIN; 1.			
CC PROSITE; PS00488; GALAPTIN; 1.			
CC PROSITE; PS00489; GALAPTIN; 1.			
CC PROSITE; PS00490; GALAPTIN; 1.			
CC PROSITE; PS00491; GALAPTIN; 1.			
CC PROSITE; PS00492; GALAPTIN; 1.			
CC PROSITE; PS00493; GALAPTIN; 1.			
CC PROSITE; PS00494; GALAPTIN; 1.			
CC PROSITE; PS00495; GALAPTIN; 1.			
CC PROSITE; PS00496; GALAPTIN; 1.			
CC PROSITE; PS00497; GALAPTIN; 1.			
CC PROSITE; PS00498; GALAPTIN; 1.			
CC PROSITE; PS00499; GALAPTIN; 1.			
CC PROSITE; PS00500; GALAPTIN; 1.			
CC PROSITE; PS00501; GALAPTIN; 1.			
CC PROSITE; PS00502; GALAPTIN; 1.			
CC PROSITE; PS00503; GALAPTIN; 1.			
CC PROSITE; PS00504; GALAPTIN; 1.			
CC PROSITE; PS00505; GALAPTIN; 1.			
CC PROSITE; PS00506; GALAPTIN; 1.			
CC PROSITE; PS00507; GALAPTIN; 1.			
CC PROSITE; PS00508; GALAPTIN; 1.			
CC PROSITE; PS00509; GALAPTIN; 1.			
CC PROSITE; PS00510; GALAPTIN; 1.			
CC PROSITE; PS00511; GALAPTIN; 1.			
CC PROSITE; PS00512; GALAPTIN; 1.			
CC PROSITE; PS00513; GALAPTIN; 1.			
CC PROSITE; PS00514; GALAPTIN; 1.			
CC PROSITE; PS00515; GALAPTIN; 1.			
CC PROSITE; PS00516; GALAPTIN; 1.			
CC PROSITE; PS00517; GALAPTIN; 1.			
CC PROSITE; PS00518; GALAPTIN; 1.			
CC PROSITE; PS00519; GALAPTIN; 1.			
CC PROSITE; PS00520; GALAPTIN; 1.			
CC PROSITE; PS00521; GALAPTIN; 1.			
CC PROSITE; PS00522; GALAPTIN; 1.			
CC PROSITE; PS00523; GALAPTIN; 1.			
CC PROSITE; PS00524; GALAPTIN; 1.			
CC PROSITE; PS00525; GALAPTIN; 1.			
CC PROSITE; PS00526; GALAPTIN; 1.			
CC PROSITE; PS00527; GALAPTIN; 1.			
CC PROSITE; PS00528; GALAPTIN; 1.			
CC PROSITE; PS00529; GALAPTIN; 1.			
CC PROSITE; PS00530; GALAPTIN; 1.			
CC PROSITE; PS00531; GALAPTIN; 1.			
CC PROSITE; PS00532; GALAPTIN; 1.			
CC PROSITE; PS00533; GALAPTIN; 1.			
CC PROSITE; PS00534; GALAPTIN; 1.			
CC PROSITE; PS00535; GALAPTIN; 1.			
CC PROSITE; PS00536; GALAPTIN; 1.			
CC PROSITE; PS00537; GALAPTIN; 1.			
CC PROSITE; PS00538; GALAPTIN; 1.			
CC PROSITE; PS00539; GALAPTIN; 1.			
CC PROSITE; PS00540; GALAPTIN; 1.			
CC PROSITE; PS00541; GALAPTIN; 1.			
CC PROSITE; PS00542; GALAPTIN; 1.			
CC PROSITE; PS00543; GALAPTIN; 1.			
CC PROSITE; PS00544; GALAPTIN; 1.			
CC PROSITE; PS00545; GALAPTIN; 1.			
CC PROSITE; PS00546; GALAPTIN; 1.			
CC PROSITE; PS00547; GALAPTIN; 1.			
CC PROSITE; PS00548; GALAPTIN; 1.			
CC PROSITE; PS00549; GALAPTIN; 1.			
CC PROSITE; PS00550; GALAPTIN; 1.			
CC PROSITE; PS00551; GALAPTIN; 1.			
CC PROSITE; PS00552; GALAPTIN; 1.			
CC PROSITE; PS00553; GALAPTIN; 1.			
CC PROSITE; PS00554; GALAPTIN; 1.			
CC PROSITE; PS00555; GALAPTIN; 1.			
CC PROSITE; PS00556; GALAPTIN; 1.			
CC PROSITE; PS00557; GALAPTIN; 1.			
CC PROSITE; PS00558; GALAPTIN; 1.			
CC PROSITE; PS00559; GALAPTIN; 1.			
CC PROSITE; PS00560; GALAPTIN; 1.			
CC PROSITE; PS00561; GALAPTIN; 1.			
CC PROSITE; PS00562; GALAPTIN; 1.			
CC PROSITE; PS00563; GALAPTIN; 1.			
CC PROSITE; PS00564; GALAPTIN; 1.			
CC PROSITE; PS00565; GALAPTIN; 1.			
CC PROSITE; PS00566; GALAPTIN; 1.			
CC PROSITE; PS00567; GALAPTIN; 1.			
CC PROSITE; PS00568; GALAPTIN; 1.			
CC PROSITE; PS00569; GALAPTIN; 1.			
CC PROSITE; PS00570; GALAPTIN; 1.			
CC PROSITE; PS00571; GALAPTIN; 1.			
CC PROSITE; PS00572; GALAPTIN; 1.			
CC PROSITE; PS00573; GALAPTIN; 1.			
CC PROSITE; PS00574; GALAPTIN; 1.			
CC PROSITE; PS00575; GALAPTIN; 1.			
CC PROSITE; PS00576; GALAPTIN; 1.			
CC PROSITE; PS00577; GALAPTIN; 1.			
CC PROSITE; PS00578; GALAPTIN; 1.			
CC PROSITE; PS00579; GALAPTIN; 1.			
CC PROSITE; PS00580; GALAPTIN; 1.			
CC PROSITE; PS00581; GALAPTIN; 1.			
CC PROSITE; PS00582; GALAPTIN; 1.			
CC PROSITE; PS00583; GALAPTIN; 1.			
CC PROSITE; PS00584; GALAPTIN; 1.			
CC PROSITE; PS00585; GALAPTIN; 1.			
CC PROSITE; PS00586; GALAPTIN; 1.			
CC PROSITE; PS00587; GALAPTIN; 1.			
CC PROSITE; PS00588; GALAPTIN; 1.			
CC PROSITE; PS00589; GALAPTIN; 1.			
CC PROSITE; PS00590; GALAPTIN; 1.			
CC PROSITE; PS00591; GALAPTIN; 1.			
CC PROSITE; PS00592; GALAPTIN; 1.			
CC PROSITE; PS00593; GALAPTIN; 1.			
CC PROSITE; PS00594; GALAPTIN; 1.			
CC PROSITE; PS00595; GALAPTIN; 1.			
CC PROSITE; PS00596; GALAPTIN; 1.			
CC PROSITE; PS00597; GALAPTIN; 1.			
CC PROSITE; PS00598; GALAPTIN; 1.			
CC PROSITE; PS00599; GALAPTIN; 1.			
CC PROSITE; PS00600; GALAPTIN; 1.			
CC PROSITE; PS00601; GALAPTIN; 1.			
CC PROSITE; PS00602; GALAPTIN; 1.			
CC PROSITE; PS00603; GALAPTIN; 1.			
CC PROSITE; PS00604; GALAPTIN; 1.			
CC PROSITE; PS00605; GALAPTIN; 1.			
CC PROSITE; PS00606; GALAPTIN; 1.			
CC PROSITE; PS00607; GALAPTIN; 1.			
CC PROSITE; PS00608; GALAPTIN; 1.			
CC PROSITE; PS00609; GALAPTIN; 1.			
CC PROSITE; PS00610; GALAPTIN; 1.			
CC PROSITE; PS00611; GALAPTIN; 1.			
CC PROSITE; PS00612; GALAPTIN; 1.			
CC PROSITE; PS00613; GALAPTIN; 1.			
CC PROSITE; PS00614; GALAPTIN; 1.			
CC PROSITE; PS00615; GALAPTIN; 1.			
CC PROSITE; PS00616; GALAPTIN; 1.			
CC PROSITE; PS00617; GALAPTIN; 1.			
CC PROSITE; PS00618; GALAPTIN; 1.			
CC PROSITE; PS00619; GALAPTIN; 1.			
CC PROSITE; PS00620; GALAPTIN; 1.			
CC PROSITE; PS00621; GALAPTIN; 1.			
CC PROSITE; PS00622; GALAPTIN; 1.			
CC PROSITE; PS00623; GALAPTIN; 1.			
CC PROSITE; PS00624; GALAPTIN; 1.			
CC PROSITE; PS00625; GALAPTIN; 1.			
CC PROSITE; PS00626; GALAPTIN; 1.			
CC PROSITE; PS00627; GALAPTIN; 1.			
CC PROSITE; PS00628; GALAPTIN; 1.			
CC PROSITE; PS00629; GALAPTIN; 1.			
CC PROSITE; PS00630; GALAPTIN; 1.			
CC PROSITE; PS00631; GALAPTIN; 1.			

KW	Acetylation; Galectin; IgB-binding protein; Lectin; Phosphorylation;				
KW	Repeat; INIT_MBT	0	0		
FT	Site	175	181		
FT	MOD_RES	1	1	Beta-galactoside binding (By similarity).	-
FT	MOD_RES	5	5	N-acetylalanine (By similarity).	-
FT	DOMAIN	34	98	Phosphoserine (By CK1) (By similarity).	-
FT	REPEAT	34	42	7 X 9 AA tandem repeats of Y-P-G-X(3)-P- [GS]-A.	-
FT	REPEAT	43	51	1.	-
FT	REPEAT	52	60	2.	-
FT	REPEAT	61	69	3.	-
FT	REPEAT	70	77	4.	-
FT	REPEAT	78	87	5 (approximate).	-
FT	REPEAT	88	98	6 (approximate).	-
FT	DOMAIN	112	244	7 (approximate).	-
FT	DISULFID	167	167	Galaptin. Interchain (By similarity).	-
SQ	SEQUENCE	244 AA;	25608 MW;	8F99BBAA0BBA7D3F CRC64;	
Query Match	Best Local Similarity	3.9%	Score 12;	DB 1;	Length 244;
Matches	12;	Conservative	100.0%;	Pred. No. 0.0011;	
Qy	55 GNDIAFHNPFRF 66	[]	Mismatches	0;	Gaps 0;
Db	146 GNDIAFHNPFRF 157				
RESULT 13					
LEG3_RAT	ID _LEG3_RAT	STANDARD;	PRT;	261 AA.	
AC	P08639;				
DT	01-JAN-1988	(Rel. 06, Created)			
DT	01-NOV-1995	(Rel. 32, Last sequence update)			
DT	25-JAN-2005	(Rel. 46, Last annotation update)			
DE	Galectin-3 (Galactose-specific lectin 3) (Mac-2 antigen) (IgB-binding protein) (35 kDa lectin) (Carbohydrate binding protein 35) (CBP 35) (Laminin-binding protein) (Lectin L-29). Name=Igals3;				
OS	Rattus norvegicus (Rat).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.				
NCBI_TaxId=10116;					
RN	[1]				
RP	SEQUENCE FROM N.A.				
RX	Medline=88016189; PubMed=2958848;				
RA	Albrandt K., Orida N.K., Liu F.-T.				
RT	"An IgB-binding protein with a distinctive repetitive sequence and homology with an IgG receptor.";				
RL	Proc. Natl. Acad. Sci. U.S.A. 82:4100-4104 (1985).				
RN	[2]				
RP	SEQUENCE OF 124-261 FROM N.A.				
RX	Medline=85216661; PubMed=3858867;				
RA	Liu F.-T., Albrandt K., Mendel E., Kulczycki A. Jr., Orida N.K.;				
RT	"Identification of an IgB-binding protein by molecular cloning."				
RL	Proc. Natl. Acad. Sci. U.S.A. 82:4100-4104 (1985).				
RN	[3]				
RP	SEQUENCE OF 119-144.				
RX	Medline=90105471; PubMed=2605254;				
RA	Lefler H., Masiarz P.R., Brondes S.H.;				
RT	"Soluble lactose-binding vertebrate lectins: a growing family."				
RL	Biochemistry 28:9222-9229 (1989).				
RN	[4]				
RP	PARTIAL SEQUENCE, AND ACETYLATION.				
RX	Medline=94075368; PubMed=8253805;				
RA	Hermann J., Turck C.W., Atchison R.E., Huflejt M.E., Poulter L., Gitt M.A., Burlingame A.L., Barondes S.H., Lefler H.;				
RT	"Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline-, glycine-, tyrosine-rich sequence with bacterial and tissue collagenase."				
RL	J. Biol. Chem. 268:26704-26711 (1993).				
CC	-I - FUNCTION: Galactose-specific lectin which binds IgE.				
CC	-I - SUBUNIT: Probably forms homo- or heterodimers. Binds LGALS3BP (By expression.");				
CC	similarity).				
CC	-I - SIMILARITY: In the C-terminal section; belongs to the galectin (Galaptin/S-lectin) family.				
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/) or send an email to license@isb-sib.ch).				
CC	EMBL; J02962; AAA4028.1; -.				
CC	HSSP; P17331; IAJ3K.				
CC	EMBL; M13637; AAA41378.1; -.				
CC	PIR; A54889; A54889.				
CC	DR SGD; 69356; Legal83.				
CC	InterPro; IPR001079; Galectin.				
CC	Prosite; PS00337; Gal-bind lectin; 1.				
CC	KW Acetylation; Direct protein sequencing; Galectin; IgB-binding protein; Lectin; Phosphorylation; Repeat.				
CC	KW Beta-galactoside binding (By similarity).				
CC	KW N-acetylalanine.				
CC	KW Phosphoserine (By CK1) (By similarity).				
CC	KW 9 X 9 AA tandem repeats of Y-P-G-X(3)-P-[GS]-[AG].				
FT	INIT_MET	0	0	Beta-galactoside binding (By similarity).	-
FT	SITE	192	198	N-acetylalanine.	-
FT	MOD_RES	1	1	Phosphoserine (By CK1) (By similarity).	-
FT	MOD_RES	5	5	9 X 9 AA tandem repeats of Y-P-G-X(3)-P-[GS]-[AG].	-
FT	DOMAIN	34	111		-
FT	REPEAT	34	42		-
FT	REPEAT	43	51		-
FT	REPEAT	52	60		-
FT	REPEAT	61	69		-
FT	REPEAT	70	78		-
FT	REPEAT	79	87		-
FT	REPEAT	88	97		-
FT	REPEAT	98	104		-
FT	REPEAT	105	111		-
FT	DOMAIN	129	261		-
FT	DISULFID	184	184		-
FT	CONFLICT	19	19		-
SQ	SEQUENCE	261 AA;	27070 MW;	EAF1175EA580D CRC64;	
Query Match	Best Local Similarity	3.9%	Score 12;	DB 1;	Length 261;
Matches	12;	Conservative	100.0%;	Pred. No. 0.0012;	Indels 0;
Qy	55 GNDIAFHNPFRF 66	[]	Mismatches 0;	Indels 0;	Gaps 0;
Db	163 GNDIAFHNPFRF 174				
RESULT 14					
QBUN97	PRELIMINARY;	PRT;	332 AA.		
AC	QBUN97;				
DT	01-MAR-2002 (T-EMBLrel. 20, Created)				
DT	01-MAR-2004 (T-EMBLrel. 26, Last annotation update)				
DE	Galectin Family_xgalectin-IVa.				
GN	Xenopus laevis (African clawed frog).				
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Xenopus.				
OC	Xenopoda; Batrachia; Anura; Mesobatrachia; Pipidae; NCBITaxonID=8355;				
OC	SEQUENCE FROM N.A.				
RA	"An IgB-binding protein with a distinctive repetitive sequence and homology with an IgG receptor.";				
RT	Proc. Natl. Acad. Sci. U.S.A. 82:4100-4104 (1985).				
RN	[1]				
RP	SEQUENCE OF 124-261 FROM N.A.				
RX	Medline=88016189; PubMed=2958848;				
RA	Albrandt K., Mendel E., Kulczycki A. Jr., Orida N.K.;				
RT	"Identify a lectin by molecular cloning."				
RL	Proc. Natl. Acad. Sci. U.S.A. 82:4100-4104 (1985).				
RN	[2]				
RP	SEQUENCE OF 119-144.				
RX	Medline=90105471; PubMed=2605254;				
RA	Lefler H., Masiarz P.R., Brondes S.H.;				
RT	"Soluble lactose-binding vertebrate lectins: a growing family."				
RL	Biochemistry 28:9222-9229 (1989).				
RN	[3]				
RP	SEQUENCE OF 124-261 FROM N.A.				
RX	Medline=85216661; PubMed=3858867;				
RA	Liu F.-T., Albrandt K., Mendel E., Kulczycki A. Jr., Orida N.K.;				
RT	"An IgB-binding protein by molecular cloning."				
RL	Proc. Natl. Acad. Sci. U.S.A. 82:4100-4104 (1985).				
RN	[4]				
RP	PARTIAL SEQUENCE, AND ACETYLATION.				
RX	Medline=94075368; PubMed=8253805;				
RA	Hermann J., Turck C.W., Atchison R.E., Huflejt M.E., Poulter L., Gitt M.A., Burlingame A.L., Barondes S.H., Lefler H.;				
RT	"Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline-, glycine-, tyrosine-rich sequence with bacterial and tissue collagenase."				
RL	J. Biol. Chem. 268:26704-26711 (1993).				
CC	-I - FUNCTION: Galactose-specific lectin which binds IgE.				
CC	-I - SUBUNIT: Probably forms homo- or heterodimers. Binds LGALS3BP (By expression.");				
CC	SEQUENCE FROM N.A.				
RA	"An IgB-binding protein with a distinctive repetitive sequence and homology with an IgG receptor.";				
RT	Proc. Natl. Acad. Sci. U.S.A. 82:4100-4104 (1985).				
RN	[1]				
RP	SEQUENCE OF 119-144.				
RX	Medline=90105471; PubMed=2605254;				
RA	Lefler H., Masiarz P.R., Brondes S.H.;				
RT	"Soluble lactose-binding vertebrate lectins: a growing family."				
RL	Biochemistry 28:9222-9229 (1989).				
RN	[2]				
RP	PARTIAL SEQUENCE, AND ACETYLATION.				
RX	Medline=94075368; PubMed=8253805;				
RA	Hermann J., Turck C.W., Atchison R.E., Huflejt M.E., Poulter L., Gitt M.A., Burlingame A.L., Barondes S.H., Lefler H.;				
RT	"Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline-, glycine-, tyrosine-rich sequence with bacterial and tissue collagenase."				
RL	J. Biol. Chem. 268:26704-26711 (1993).				
CC	-I - FUNCTION: Galactose-specific lectin which binds IgE.				
CC	-I - SUBUNIT: Probably forms homo- or heterodimers. Binds LGALS3BP (By expression.");				

RL Glycobiology 12:163-172 (2002).
 - SIMILARITY: Belongs to the galectin (galaptin/S-lectin) family.
 EMBL: AB060972; BAB83259.1; -.
 DR HSSP; P17931; 1A3K.
 DR GO:000972; GO:005529; F:sugar binding; IEA.
 GO; GO:005529; F:sugar binding; IEA.
 Pfam: PF00337; Gal-bind lectin; 2.
 SMART: SM00276; GLECT; 2.
 DR GAlectin; Lectin.
 KW Lectin.
 SEQUENCE 332 AA; 36822 MN; D273FB035484E9C2 CRC64;

Query Match 3.5%; Score 11; DB 2; Length 332;
 Best Local Similarity 100.0%; Pred. No. 0.017; No. 0.018;
 Matches 11; Conservative 0; Mismatches 0; Gaps 0; Indels 0; Gaps 0;

QY 56 NDIAFHFNPRF 66
 Db 50 NDIAFHFNPRF 60

RESULT 15
 Q6PGR5 PRELIMINARY ;
 ID Q6PGR5 PRT; 353 AA.
 AC Q6PGR5;
 DT 05-JUL-2004 (TREMBLrel. 27, Created)
 DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
 DE Xgalectin-iva Protein (Fragment).
 CN Name=xgalectin iva.
 OS Xenopus laevis (African clawed frog).
 EUkaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
 Xenopodinae; Xenopidae;
 OX NCBI_TaxID=8355;

[1] RN
 RP SEQUENCE FROM N.A.
 RC TISSUE=Whole;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Klausner R.D., Reingold E.A., Grouse L.H., Degege J.G., Schaefer C.F., Bhattacharya S., Shemesh C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Wagner L., Shenmeh C.M., Bhat N.K., Hopkins R.P., Jordan H., Moore T., Max S.I., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Ronald M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Ubdin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullah S.J., Bosak S.A., McEwan P.J., McEwan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Murzy D.M., Sodergren E.J., Lu X., Gibbs R.A., Paley J., Heitton B., Ketteman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmitz J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Shalska U., Smailus D.E., Schnierch A., Schein J.E., Jones S.J., Marra M.A.; "Generation and initial analysis of more than 15,000 full-length human RT and mouse cDNA sequences." Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).

RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Whole;
 RX MEDLINE=22341132; PubMed=12454917; DOI=10.1002/dvdy.10174
 RA Klein S.L., Strausberg R.L., Wagner L., Pontius J., Clifton S.W., Richardson P.; "Genetic and genomic tools for Xenopus research: The NIH Xenopus RT initiative." Dev. Dyn. 225:384-391 (2002).

RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Whole;
 RA Klein S., Strausberg R.; Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
 CC -1- SIMILARITY: Belongs to the galectin (galaptin/S-lectin) family.

GenCore version 5.1.6	Aaw61614	Human gal						
Copyright (c) 1993 - 2005 Compugen Ltd.	Abu69163	Human NOV						
protein - protein search, using SW model	Abd08329	Ado08329						
on on:	July 13, 2005, 07:46:47 ; Search time 163 Seconds (without alignments)	Abg43992 Human can						
oring table:	OLIGO	Abp06703 Novel hum						
Gapop 60.0 , Gapext 60.0	Adb62650 Rat urate							
arched:	2105632 seqs, 386760381 residues	Aoc53848 Rat Galec						
rd size :	0	Ade62927 Rat Prote						
total number of hits satisfying chosen parameters:	2105692	Adc49099 Rat Prote						
minimum DB seq length: 0		Ade57164 Rat Prote						
maximum DB seq length: 2000000000		Ade57162 Rat Prote						
st-processing: Listing first 45 summaries		Abw01522 Protein #						
database :		Aog40248 Rat Galec						
A_Geneseq_16Dec04:*		Abb77857 Amino aci						
1: geneseqp1980s:*		Abb77856 Amino aci						
2: geneseqp1980s:*		Abb77855 Amino aci						
3: geneseqp2004s:*		Aau97036 Human bla						
4: geneseqp2001s:*		Adc53842 Mouse gal						
5: geneseqp2002s:*		Aap60534 C-terminal						
6: geneseqp2003as:*		Adn17285 Hamster g						
7: geneseqp2003bs:*								
8: geneseqp2004s:*								
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.								
SUMMARIES								
sult	No.	Score	Query	Match	Length	DB	ID	Description
1	311	100.0	AAW56504	311	2			Aaw61614 Human gal
2	306	98.4	ABP77854	311	5	ABP77854	Amino aci	Abg43994 Human gal
3	163	52.4	ADP61097	233	8	ADP61097	Protein O	Abp06703 Novel hum
4	163	52.4	AAV56802	323	3	AAV56802	Human eos	Aay06997 Galectin-1
5	163	52.4	ABP77853	323	5	ABP77853	Amino aci	Aaw85664 Galectin-2
6	163	52.4	ABP61494	323	5	ABP61494	Human NF- κ B	Abp06730 Novel hum
7	163	52.4	ADQ66730	323	8	ADQ66730	Human Pro	Aay06297 Galectin-3
8	163	52.4	AAV06997	355	2	AAV06997	Human lec	Abp77852 Amino aci
9	163	52.4	AAW56664	355	2	AAW56664	Human lun	Abp77852 Amino aci
10	163	52.4	ABP77852	355	7	ABP77852	Human lun	Adc53845 Human gal
11	163	52.4	ADC53845	355	7	ADC53845	Human lun	Adp53845 Human gal
12	163	52.4	ADP62929	355	7	ADP62929	Human col	Aab1899 Human col
13	163	52.4	ADD48101	355	7	ADD48101	Human Pro	Adq4496 Colon tum
14	163	52.4	ADG91608	355	7	ADG91608	Human lec	Adg91608 Human col
15	163	52.4	AAB13847	378	4	AAB13847	Human lun	Adb66747 Human lun
16	163	52.4	ADP66747	378	4	ADP66747	Human lun	Adp12958 Protein e
17	163	52.4	ADE88001	378	7	ADE88001	Human lun	Abp08331 Human NOV
18	148	47.6	ABU69164	168	3	ABU69164	Human NOV	Aaw61613 Human gal
19	148	47.6	ABM24496	168	4	ABM24496	Human NOV	Abp08331 Human NOV
20	148	47.6	ABP55345	168	6	ABP55345	Human col	Aab24496 Colon tum
21	148	47.6	ABU63651	301	5	ABU63651	Human ura	Abp55345 Human col
22	87	28.0	ADP12958	323	8	ADP12958	Protein e	Adp12958 Protein e
23	73	23.5	ABU69164	246	6	ABU69164	Human NOV	Aab1899 Human col
24	73	23.5	ABU69164	246	8	ABU69164	Human NOV	Aaw61613 Human gal
25	69	22.2	ABU69164	245	8	ABU69164	Human NOV	Abp08331 Human NOV

CC sequence was deduced from a human adult pancreatic tumour cDNA clone (see
 CC claims (see AAW5503-06)). Novel galectins 8, 9, 10 and 10Sv variant (10Sv) are
 CC claimed by expression in recombinant host cells. The novel galectins are used in
 CC a claimed method for treating a cell growth disorder, especially cancer,
 CC autoimmune diseases, inflammatory diseases, asthma, and allergic
 CC diseases, in a mammal. They are especially useful for diagnosis of
 CC melanoma, renal astrocytoma, Hodgin disease, and breast, ovarian,
 CC prostate, bone, liver, lung, pancreatic and splenic cancers; The
 CC invention further relates to screening methods for identifying agonists
 CC and antagonists of galectin 8, 9, 20 or 10Sv activity, and to diagnostic
 CC methods involving estimating levels of galectin 8, 9, 10 or 10Sv protein
 CC or mRNA.

XX Sequence 311 AA;
 SQ Score 311; DB 2; Length 311;

Best Local Similarity 100.0%; Pred. No. 4.1e-305; Length 311;
 Matches 311; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAFSGSOAIPYLSPAVPFSCTIGGLQDGIIQTGVTLVSSSGTRPAVNFGTGFSGNDIAF 60

Db 1 MAFSSQAPPYLSPAVPFSCTIGGLQDGIIQTGVTLVSSSGTRPAVNFGTGFSGNDIAF 60

Qy 61 HENPREFDGGYVVCNTRONSWGPBEEKTHMPFKGMPFDLCPFLVQSSDFKVMNGILFV 120

Db 61 HENPREFDGGYVVCNTRONSWGPBEEKTHMPFKGMPFDLCPFLVQSSDFKVMNGILFV 120

Qy 121 QYFHRRVPFRVDTISVNGSVQLSISFOTOTVHTVQSAQGMESTPAIPLPMYPHPAYP 180

Db 121 QYFHRRVPFRVDTISVNGSVQLSISFOTOTVHTVQSAQGMESTPAIPLPMYPHPAYP 180

Qy 181 MPFTITLGGLYPSKSILLSGTVPFLPSAQRFHNLNPRFDENAVVRNTQD 240

Db 181 MPFTITLGGLYPSKSILLSGTVPFLPSAQRFHNLNPRFDENAVVRNTQD 240

Qy 241 NSWGBERSSLPRKMPFVRGOSFSWILCRAHCLKVADQQLPEYYHRNLPTINRLEY 300

Db 241 NSWGBERSSLPRKMPFVRGOSFSWILCRAHCLKVADQQLPEYYHRNLPTINRLEY 300

Qy 301 GGDIOQTHYQT 311

Db 301 GGDIOQTHYQT 311

RESULT 2
 ID ABB77854 standard; protein; 311 AA.

XX ABB77854;

XX DT 27-SEP-2002 (first entry)

XX DE Amino acid sequence of a human protein.

XX Cancer; galectin 9; antibody; skin cancer; melanoma; breast cancer;

XX ovarian cancer; uterus cancer; tumour; prostate cancer; bladder cancer;

XX kidney cancer; thyroid cancer; throat cancer; tongue cancer;

XX upper jaw cancer; esophageal cancer; stomach cancer; colon cancer;

XX lung cancer; liver cancer; gall-bladder cancer; pancreatic cancer;

XX leukemia; liposarcoma; glioma.

XX Homo sapiens.

XX WO200237114-A1.

XX PN 10-MAY-2002.

XX PR 31-OCT-2001; 2001WO-JP009561.

XX DE 01-NOV-2000; 2000JP-00335077.

XX PA (GALP-) GALPHARMA CO LTD.

XX	Hirashima M, Yamauchi A, Kagesita T, Nakamura T, Nishi N;
PI	
XX	WPI; 2002-51265/55.
XX	Metastasis mechanism-based agents (anti-galectin 9 antibody) for detecting ability of cancer to metastasize in cells, uses galectin 9 as marker to detect cancer metastasis for diagnosis, cancer prevention and treatment.
XX	Disclosure; Page 63-64; 68pp; Japanese.
PS	
XX	The specification describes an agent for detecting the ability of cancers to metastasize. This agent comprises anti-galectin 9 antibody as the active ingredient. The agents and method are for or detecting ability of cancer to metastasize in cancer cells, which are useful in the diagnosis, prevention and treatment of cancer. The cancer includes epithelial malignant tumours (tumourising or non-tumourising) in organs, tissues or blood. Such cancer can be 1 of the not less than 31 specifically claimed, e.g. skin cancer (including melanoma), breast cancer, ovarian cancer, uterus cancer, malignant tumour of the testis, prostate cancer, bladder cancer, kidney cancer, thyroid cancer, cancer of throat and larynx, tongue cancer, upper jaw cancer, esophageal cancer, stomach cancer, rectum cancer, lung and bronchus cancer, liver cancer (including hepatocarcinoma and intrahepatic biliary cancer), extrahepatic biliary duct and gall-bladder cancer, pancreatic cancer, leukemia, malignant lymphoma, liposarcoma and glioma. The cancer cells are particularly breast cancer cells or melanoma cells. The present sequence represents a human protein, which is used in the course of the invention
CC	
CC	Sequence 311 AA;
SQ	
Query Match 98.4%; Score 306; DB 5; Length 311;	
Best Local Similarity 100.0%; Pred. No. 4.6e-300;	
Matches 306; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Db	
Qy 6 SQAPYLSPAPPFSCSTIQGLQDGIIQTGVTLVSSSGTRPAVNFGTFSGNDIAFHENP 65	
Db 6 SQAPYLSPAPPFSCSTIQGLQDGIIQTGVTLVSSSGTRPAVNFGTFSGNDIAFHENP 65	
Db	
Qy 66 FEDGGVVCNTRONSWGPBEEKTHMPFKGMPFDLCPFLVQSSDFKVMNGILFVQYFHR 125	
Db 66 FEDGGVVCNTRONSWGPBEEKTHMPFKGMPFDLCPFLVQSSDFKVMNGILFVQYFHR 125	
Db	
Qy 126 VPFHRDTISVNGSVQLSISFOTOTVHTVQSAQGMESTPAIPLPMYPHPAYPMPFT 185	
Db 126 VPFHRDTISVNGSVQLSISFOTOTVHTVQSAQGMESTPAIPLPMYPHPAYPMPFT 185	
Db	
Qy 186 TILGGLYPSKSILLSGTVLPSAQRFHNLNPRFDENAVVRNTQD 245	
Db 186 TILGGLYPSKSILLSGTVLPSAQRFHNLNPRFDENAVVRNTQD 245	
Db	
Qy 246 EERSLPRKMPFVRGOSFSWILCEAHCLKVADQQLPEYYHRNLPTINRLEVGGDQ 305	
Db 246 EERSLPRKMPFVRGOSFSWILCEAHCLKVADQQLPEYYHRNLPTINRLEVGGDQ 305	
Db	
Qy 306 LTHYQT 311	
Db 306 LTHYQT 311	
RESULT 3	
ID ADP1097	
XX ADP1097 standard; protein; 233 AA.	
AC	
XX DT 09-SEP-2004 (first entry)	
DE Protein of human ovarian specific gene, SEQ ID No 131.	
XX normal; neoplastic; ovarian; specific nucleic acid; OSNA;	
KW metastatic; cancer; vaccine; cytostatic; human.	

RESULT 4									
OS Homo sapiens.	ID AAY56802	XX standard; protein;	XX 323 AA.						
PN WO2004053079-A2.	ID AAY56802	XX	XX						
XX 24-JUN-2004.	ID AAY56802	XX	XX						
XX DR 08-DEC-2003; 20031WO-US0388855.	ID AAY56802	XX	XX						
XX PR 06-DBC-2002; 2002US-0431301P.	ID AAY56802	XX	XX						
XX PR 06-DEC-2002; 2002US-0431321P.	ID AAY56802	XX	XX						
XX PR 30-JUN-2003; 2003US-0484588P.	ID AAY56802	XX	XX						
XX PR 07-NOV-2003; 2003US-0518607P.	ID AAY56802	XX	XX						
XX (DIAD-) DIADEXUS INC.	ID AAY56802	XX	XX						
XX PI Macina RA, Turner LR, Sun Y, Liu S, Chen H,	ID AAY56802	XX	XX						
XX XX WPI; 2004-468850/44.	ID AAY56802	XX	XX						
XX DR N-PSDB; ADP80968.	ID AAY56802	XX	XX						
XX New ovarian specific nucleic acid molecules and polypeptides useful for diagnosing, preventing or treating ovarian cancer, for producing transgenic animals or cells, or for research purposes.	ID AAY56802	XX	XX						
XX PT Claim 12; SEQ ID NO 131; 754pp; English.	ID AAY56802	XX	XX						
PS 05 The invention relates to novel isolated nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells. These CC sequences a nucleic acid sequence encoding any of the 167 amino acid CC sequences (e.g. 438, 237 or 233 amino acids) fully defined in the CC specification (SEQ. ID NOS: ADP81095 to ADP81261) and comprises any of CC the 128 nucleotide sequences (e.g. 1478, 1494 or 1691 bp) fully defined in the CC specification (SEQ. ID NOS: ADP80967 to ADP81094). The invention CC further comprises: a method for determining the presence of a ovarian CC specific nucleic acid (OSNA) in a sample; a vector comprising the above CC nucleic acid molecule; a host cell comprising the vector; a method for CC producing a polypeptide encoded by the above nucleic acid molecule; a CC polypeptide encoded by the nucleic acid molecule cited above; an antibody CC or its fragment that specifically binds to the above polypeptide; a CC method for determining the presence of an ovarian specific protein in a CC sample; a method for diagnosing or monitoring the presence and metastases CC of ovarian cancer in a patient; a kit comprising a means for determining the presence of the above nucleic acid molecule or CC polypeptide; a method of treating a patient with ovarian cancer; and a CC vaccine comprising the above polypeptide or nucleic acid encoding the CC polypeptide. The isolated polypeptides may be used to create a CC cytostatic activity. The isolated polypeptides may be used to create a CC vaccine. The isolated nucleic acid molecules and polypeptides can be used CC for diagnosing or monitoring the presence and metastases of ovarian CC cancer and treating ovarian cancer. This sequence represents the protein CC of an ovarian specific gene of the invention.	ID AAY56802	XX	XX						
XX Sequence 233 AA;	ID AAY56802	XX	XX						
XX Query Match 52.4%; Score 163; DB 8; Length 233;	ID AAY56802	XX	XX						
XX Best Local Similarity 100.0%; Pred. No. 8.7e-156;	ID AAY56802	XX	XX						
XX Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	ID AAY56802	XX	XX						
Qy 149 TOTVIHTYQSAPQMFPSTPAIPPMYTPHPAYPMPPFTTILGGLYPSKSILLSGTVLPSAQ	ID AAY56802	XX	XX						
Db 71 TOTVIHTYQSAPQMFPSTPAIPPMYTPHPAYPMPPFTTILGGLYPSKSILLSGTVLPSAQ	ID AAY56802	XX	XX						
Qy 209 RPHINLGSGNHAIFHNPREDENAVRNTQIDNSWGSBEERSLPRKMPFVYQGFSWILC	ID AAY56802	XX	XX						
Db 221 RPHINLGSGNHAIFHNPREDENAVRNTQIDNSWGSBEERSLPRKMPFVYQGFSWILC	ID AAY56802	XX	XX						
Qy 269 EAHCLKVAVDGQHLEYTHRLNPLTNRLEVGGDIOQTHVQT	ID AAY56802	XX	XX						
Db 281 EAHCLKVAVDGQHLEYTHRLNPLTNRLEVGGDIOQTHVQT	ID AAY56802	XX	XX						
Qy 209 RPHINLGSGNHAIFHNPREDENAVRNTQIDNSWGSBEERSLPRKMPFVYQGFSWILC	ID AAY56802	XX	XX						
Db 131 RPHINLGSGNHAIFHNPREDENAVRNTQIDNSWGSBEERSLPRKMPFVYQGFSWILC	ID AAY56802	XX	XX						
Qy 269 EAHCLKVAVDGQHLEYTHRLNPLTNRLEVGGDIOQTHVQT	ID AAY56802	XX	XX						
Db 191 EAHCLKVAVDGQHLEYTHRLNPLTNRLEVGGDIOQTHVQT	ID AAY56802	XX	XX						
RESULT 5									
DB ABB77853	ID ABB77853	XX standard; protein;	XX 323 AA.						
XX AC ABB77853;	ID ABB77853	XX	XX						
XX 27-SEP-2002 (first entry)	ID ABB77853	XX	XX						

Amino acid sequence of a human protein.

DE Cancer; galectin 9; antibody; skin cancer; melanoma; breast cancer; ovarian cancer; uterus cancer; tumour; prostate cancer; bladder cancer; kidney cancer; thyroid cancer; throat cancer; tongue cancer; upper jaw cancer; esophageal cancer; stomach cancer; colon cancer; lung cancer; liver cancer; gall-bladder cancer; pancreatic cancer; leukemia; liposarcoma; glioma.

XX Homo sapiens.

XX OS

XX PN WO200237114-A1.

XX XX

XX PD 10-MAY-2002.

XX XX

XX PF 31-OCT-2001; 2001WO-JP009561.

XX XX

XX PR 01-NOV-2000; 2000JP-00335077.

XX PR

XX PA (GALP-) GALPHARMA CO LTD.

XX XX

XX PI Hirashima M, Yamauchi A, Kageshita T, Nakamura T, Nishi N;

XX DR WPI; 2002 519265/55.

XX XX

XX PT Metastasis mechanism-based agents (anti-galectin 9 antibody) for detecting ability of cancer to metastasize in cells, uses Galactin 9 as marker to detect cancer metastasis for diagnosis, cancer prevention and treatment.

XX XX

XX PS Example 5; Page 61-63; 68pp; Japanese.

XX XX

CC The specification describes an agent for detecting the ability of cancer to metastasize. This agent comprises anti-galectin 9 antibody as the active ingredient. The agents and method are for or detecting ability of cancer to metastasize in cancer cells, which are useful in the diagnosis, prevention and treatment of cancer. The cancer includes epithelial malignant tumours (tumourising or non-tumourising) in organs, tissues or blood. Such cancer can be 1 of the not less than 31 specifically claimed e.g. skin cancer (including melanoma), breast cancer, ovarian cancer, uterus cancer, malignant tumour of the testis, prostate cancer, bladder cancer, kidney cancer, thyroid cancer, cancer of throat and larynx, tongue cancer, upper jaw cancer, esophageal cancer, stomach cancer, colon and rectum cancer, lung and bronchus cancer, liver cancer (including hepatocarcinoma and intrahepatitic biliary cancer), extrahepatic biliary duct and gall-bladder cancer, pancreatic cancer, leukemia, malignant lymphoma, liposarcoma and glioma. The cancer cells are particularly breast cancer cells or melanoma cells. The present sequence represents human protein, which is used in the course of the invention

XX	SQ	Sequence	323 AA;
		Query Match	52.4% ; Score 163; DB 5; Length 323;
		Best Local Matches	100.0% ; Pred. No. 1.e-155;
		Conservative Matches	0; Mismatches 0; Indels 0
Qy	149	TQTVIHTVQSAPQMSTPAIPMMYPPAYPMPFPITTLGGLYPSKSILLSL	
	161	TQTVIHTVQSAPQMSTPAIPMMYPPAYPMPFPITTLGGLYPSKSILLSL	
Qy	209	RPHINLCGNGHIAFHNLNPRFDENAVRNTQIDNSWGSEERSLPRKMPFVRGQ	
	221	RPHINLCGNGHIAFHNLNPRFDENAVRNTQIDNSWGSEERSLPRKMPFVRGQ	
Qy	269	EAHCLKYAVDGFOLFEYFHRLNPLTINLEVGDIQLTHVQT	311
	281	EAHCLKYAVDGFOLFEYFHRLNPLTINLEVGDIQLTHVQT	323
		RESULT 6	
		ABP61494	
XX		ID ABP61494 standard; protein: 323 AA.	

AC ABP61494;
 XX DT 30-SEP-2002 (first entry)
 XX DE Human NF- κ B activating protein SEQ ID NO 141.
 XX KW Human; NF- κ B; nuclear factor kappa B; mouse; antiinflammatory;
 XX immunomodulator; cytotoxic; antiinfective; osteopathic; nootropic;
 XX neuroprotective; anti-HIV; autoimmune disease; cancer; infection;
 XX bone disease; AIDS; neurodegenerative disease; ischaemic disorder
 XX OS Homo sapiens.
 XX PN WO20025737-A1.
 XX PD 11-JUL-2002.
 XX PF 25-DEC-2001; 2001WO-JB011389.
 XX PR 28-DEC-2000; 2000JP-00402288.
 PR 26-MAR-2001; 2001JP-00088912.
 PR 24-AUG-2001; 2001JP-00254018.
 XX PA (ASAH) ASAHI KASEI KOGYO KK.
 XX PI Matsuda A, Honda G, Muramatsu S, Nagano Y;
 XX WPT; 2002-583617/62.
 DR N-PSDB; ABQ91982.
 XX PT NF- κ B activating gene and expressed protein, applical
 PT diagnosis and screening inhibitors or promoters to control excessive
 PT activation or inhibition for treating e.g. inflammations, autoimmu-
 PT nities and cancer.
 XX PS Claim 1, Page 613-615; 841pp; Japanese.
 XX CC The invention relates to a purified protein (I), comprising one or
 CC fully defined sequences (ABP61424-ABP61511) or a protein based on
 CC the sequences but with some amino acids deleted, substituted or ac-
 CC with a NF- κ B (nuclear factor kappa B) activating effect. The proto-
 CC encoding gene (ABQ91912-ABQ92001) are useful in diagnosis and scre-
 CC ning. Inhibitors or promoters to control excessive activation or inhibi-
 CC tion for treating e.g. inflammations, autoimmune diseases, cancers,
 CC infections, bone diseases, AIDS, neurodegenerative diseases or is-
 CC chaeamic disorders
 XX Sequence 323 AA;

RESULT 7						
Query	Match	Score	DB	Length	AA	
Yy	149 TQTVIHTYQSAPQMFSTPAIPAIIMMYPHPAYPMFIFTITLGGIYPSKSIIISGTVLPSAQ	52.4%	208	163;	DB 5;	Length 323;
Yy	161 TQTVIHTYQSAPQMFSTPAIPAIIMMYPHPAYPMFIFTITLGGIYPSKSIIISGTVLPSAQ	100.0%	220	100.0%;	Pred No. 1.2e-155;	
Yy	163; Conservative	0;		Mismatches 0;	Indels 0;	Gaps 0;
Db	169 EAHCLKVAVDGQLFETYHLRLNLPTRNLLEVGGDIDLTHVQT	311	268	RPHINLCSGNHIAFHLMNRDENAVRVTQIDNSWGSERSLSPKXMPFVRGQFSWVILC	268	
Db	209 RPHINLCSGNHIAFHLMNRDENAVRVTQIDNSWGSERSLSPKXMPFVRGQFSWVILC	268	280	RPHINLCSGNHIAFHLMNRDENAVRVTQIDNSWGSERSLSPKXMPFVRGQFSWVILC	280	
Yy	221 RPHINLCSGNHIAFHLMNRDENAVRVTQIDNSWGSERSLSPKXMPFVRGQFSWVILC	280				
Db	269 EAHCLKVAVDGQLFETYHLRLNLPTRNLLEVGGDIDLTHVQT	311	281	EAHCLKVAVDGQLFETYHLRLNLPTRNLLEVGGDIDLTHVQT	323	
ADQ666730 standard; protein; 323 AA.						
	XX	XX	XX	XX	XX	XX
	AC	AC	AC	AC	AC	AC
	DT	DT	DT	DT	DT	DT
	07-OCT-2004	(first entry)				

XX Novel human protein sequence #1703.
 XX
 KW osteoprotective; nootropic; antiparkinsonian; cytostatic;
 KW gene therapy; diagnostic marker; morbid state; osteoporosis;
 KW neurological disease; Alzheimer's disease; Parkinson's disease; dementia;
 XX cancer.
 OS *Homo sapiens*.
 PN EP1440981-A2.
 XX 28-JUL-2004.
 PD 21-JAN-2004; 2004EP-00001196.
 PR 21-JAN-2003; 2003JP-00102206.
 PR 09-MAY-2003; 2003JP-00131392.
 XX (REAS-) RES ASSOC BIOTECHNOLOGY.
 PI Isogai T, Sugiyama T, Otsuki T, Wakamatstu A, Sato H, Ishii S;
 PI Yamamoto J, Isono Y, Nagai K, Irie R;
 DR WPI; 2004-535376/52.
 DR N-PSDB; ADQ64542.

XX Novel 2495 cDNA, useful for treating osteoporosis, neurological diseases, Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
 PT XX
 PS Claim 1; SEQ ID NO 3891; 2449pp; English.
 XX The invention relates to 2495 novel polynucleotides (I) and their encoded polypeptides, sequences hybridizing to these nucleotides, sequences encoding partial polypeptides and sequences having 70% or 90% identity to the nucleotide and protein sequences. The nucleotides and polypeptides are useful as diagnostic markers or therapeutic target for the diseases or morbid states. They are also useful for treating osteoporosis, neurological diseases, Alzheimer's diseases, Parkinson's diseases, dementia and various cancers. This sequence corresponds to a protein sequence of the invention.
 XX Sequence 323 AA;
 SQ Query Match 52.4%; Score 163; DB 8; Length 323;
 Best Local Similarity 100.0%; Pred. No. 1.2e-155;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 SQ Sequence 355 AA;
 Query Match 52.4%; Score 163; DB 2; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.3e-155;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTVIHTVQSAPGMFSTPAIPPMYPPHAYPMPFITTLGGLYPSKSILLSGTYLPSAQ 208
 Db 161 TQTVIHTVQSAPGMFSTPAIPPMYPPHAYPMPFITTLGGLYPSKSILLSGTYLPSAQ 220

Qy 209 RFHINLCSGNHIAFHNLNPREDENAVRTNTQIDNSNGSERSLPRKMPFVRGQSFPSWILC 268
 Db 221 RFHINLCSGNHIAFHNLNPREDENAVRTNTQIDNSNGSERSLPRKMPFVRGQSFPSWILC 280

Qy 269 EAHCLKVADQQLPFFYHLRNLNPTINLEVGDIQLTHVQT 311
 Db 281 EAHCLKVADQQLPFFYHLRNLNPTINLEVGDIQLTHVQT 323

RESULT 8
 AAY06997 standard; protein; 355 AA.
 AC AAY06997;
 XX 02-JUL-1999 (First entry)
 DE Galectin-9 protein sequence.
 KW Cancer associated antigen; diagnosis; research; treatment; human;
 KW breast cancer; colon cancer; gastric cancer; renal cancer; lung cancer;

XX prostate cancer.
 XX Homo sapiens.
 XX
 PN WO9904265-A2.
 XX 28-JAN-1999.
 PD
 XX 15-JUL-1998; 98WO-US014679.
 PR 17-JUL-1997; 97US-00836164.
 PR 10-OCT-1997; 97US-0061599P.
 PR 10-OCT-1997; 97US-0061765P.
 PR 10-OCT-1997; 97US-0098705.
 PR 11-OCT-1997; 97GB-0021697.
 PR 22-JUN-1998; 98US-00102322.
 XX (LUDW-) LUDWIG INST CANCER RES.
 PA Old LJ, Scanlan MJ, Stockert E, Gure A, Chen Y, Gout I;
 PI O'hare M, Obata Y, Pfreundschuh M, Tureci O, Sahin U;
 DR WPI; 1999-132448/11.
 DR N-PSDB; AAX40198.

XX New isolated cancer associated nucleic acids and polypeptides - isolated using sera from cancer patients, used to develop products for the diagnosis, monitoring or treatment of cancers.
 PT XX
 PT New isolated cancer associated nucleic acids and polypeptides - isolated using sera from cancer patients, used to develop products for the diagnosis, monitoring or treatment of cancers.
 Example 8; Page 779-780; 787pp; English.

XX The invention relates to a method for diagnosing a disorder characterised by expression of a human cancer associated antigen precursor coded for by a nucleic acid molecule (NAM). The method comprises: (a) contacting a biological sample isolated from a subject with an agent that specifically binds to the NAM, an expression product or a fragment of an expression product complexed with an HLA molecule; and (b) determining the interaction between the agent and the NAM or the expression product as a determination of the disorder. The products and methods can be used in the diagnosis, monitoring, research, or treatment of conditions characterised by the expression of various cancer associated antigens. The invention provides nucleic acid sequences and encoded polypeptides which are cancer associated antigen precursors expressed in human breast cancer, renal cancer, colon cancer, gastric cancer, prostate cancer and lung cancer.

XX Query Match 52.4%; Score 163; DB 2; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.3e-155;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 149 TQTVIHTVQSAPGMFSTPAIPPMYPPHAYPMPFITTLGGLYPSKSILLSGTYLPSAQ 208
 Db 161 TQTVIHTVQSAPGMFSTPAIPPMYPPHAYPMPFITTLGGLYPSKSILLSGTYLPSAQ 220

Qy 149 TQTVIHTVQSAPGMFSTPAIPPMYPPHAYPMPFITTLGGLYPSKSILLSGTYLPSAQ 208
 Db 193 TQTVIHTVQSAPGMFSTPAIPPMYPPHAYPMPFITTLGGLYPSKSILLSGTYLPSAQ 252

Qy 209 RFHINLCSGNHIAFHNLNPREDENAVRTNTQIDNSNGSERSLPRKMPFVRGQSFPSWILC 268
 Db 221 RFHINLCSGNHIAFHNLNPREDENAVRTNTQIDNSNGSERSLPRKMPFVRGQSFPSWILC 280

Qy 209 RFHINLCSGNHIAFHNLNPREDENAVRTNTQIDNSNGSERSLPRKMPFVRGQSFPSWILC 268
 Db 253 RFHINLCSGNHIAFHNLNPREDENAVRTNTQIDNSNGSERSLPRKMPFVRGQSFPSWILC 312

Qy 269 EAHCLKVADQQLPFFYHLRNLNPTINLEVGDIQLTHVQT 311
 Db 313 EAHCLKVADQQLPFFYHLRNLNPTINLEVGDIQLTHVQT 355

RESULT 9
 AAW85664
 ID AAW85664 Standard; protein; 355 AA.
 XX
 AC AAW85664;
 DE AAW85664;
 DT 19-JUL-1999 (first entry)

DE	Galectin-9 like protein.
XX	Galectin-9; lectin; galactose; Hodgkin's disease; pharmaceutical; sugar chain; intercellular adhesion; cell proliferation.
KW	
XX	
OS	Homo sapiens.
XX	
IPN	WO9910490-A1.
XX	
PD	04-MAR-1999.
XX	
PPF	19-AUG-1998;
XX	98WO-JP003670.
PR	22-AUG-1997;
XX	97JP-00226468.
PA	(SAGA) SAGAMI CHEM RES CENTRE. (PROT-) PROTEGENE INC.
PA	
XX	
PPI	Kato S, Yamaguchi T, Sekine S, Kamata K;
XX	
DDR	WPI; 1999-226913/19.
N-PSDB	N-PSDB; AAX08490, AAX08491.
XX	
PPT	A new human protein having lactose binding properties.

Claim 2; Page 55-57; 64pp; English.

Galecins are the general term for animal lectins binding to galactosides in many sites such as the cytoplasm, the nucleus, the cell membrane etc. and are considered to be associated with cell proliferation. Galecint-9 has been identified as an antigenic protein reacting with an antibody contained in the serum of Hodgkin's disease patients. Galecint-9 in the body has not been completely identified but is thought to be involved in intercellular adhesion. The human Galecint-9 like protein coding sequences are characterised by containing the sequence described in A/X0849. This protein can be used as pharmaceuticals or reagents for sugar chain research. The cDNA is used as a probe for gene diagnosis and for therapy.

Sequence 355 AA;	
SQ	Query Match 52.4%; Score 163; DB 2; Length 355;
	Best Local Similarity 100.0%; Prcd. No. 1.3e-15;
	Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy	149 TQTVIHTVQSAPGQMSTAIPIPPMYPHPAYNPFTTLLGGYPSKSILLSGTIVL
D _b b	193 TQTVIHTVQSAPGQMSTAIPIPPMYPHAYNPFTTLLGGYPSKSILLSGTIVL
Qy	209 RFHINLCSGNHIAFLNPNPFDENAVVRNTIQDNSWGSEERSLPRKMPFVRGOSFSVW
D _b b	253 RFHINLCSGNHIAFLNPNPFDENAVVRNTIQDNSWGSEERSLPRKMPFVRGOSFSVW
Qy	269 EAHCIVKAVDGOHLFEYHYRLRNLIPTNLVEGGDIOLTHVQT 3.1.1
D _b b	313 EAHCIVKAVDGOHLFEYHYRLRNLIPTNLVEGGDIOLTHVQT 3.5.5

RESULT 10
ABB77852
סמסטר 2 סטודנטים 255 נו.

ABD / 032 Standard; protein; 355 AA.	
XX	
AC	ABB77852;
XX	
DT	27-SEP-2002 (first entry)
XX	
DE	Amino acid sequence of a human protein.
XX	
KW	Cancer; galectin 9; antibody; skin cancer; melanoma; breast cancer
KW	ovarian cancer; uterus cancer; tumour; prostate cancer; bladder cancer
KW	kidney cancer; thyroid cancer; throat cancer; tongue cancer;
KW	

KW upper jaw cancer; esophageal cancer; stomach cancer; colon cancer;
 KW lung cancer; liver cancer; gall-bladder cancer; pancreatic cancer;
 KW leukemia; liposarcoma; glioma.
 XX OS Homo sapiens.
 XX PN WO200237114-A1.
 XX PD 10-MAY-2002.
 XX PR 31-CCT-2001; 2001WO-JP009561.
 XX PR 01-NOV-2000; 2000JP-00335077.
 XX PA (GALP-) GALPHARMA CO LTD.
 XX PI Hirashima M, Yamauchi A, Kagesita T, Nakamura T, Nishi N;
 XX DR ; 2002-519265/55.
 XX PT Metastasis mechanism-based agents (anti-galectin 9 antibody) for
 PT detecting ability of cancer to metastasize in cells, uses galectin 9 as
 PT marker to detect cancer metastasis for diagnosis, cancer prevention and
 PT treatment.
 XX PS Example 1; Page 60-61; 68pp; Japanese.
 XX CC The specification describes an agent for detecting the ability of cancers
 CC to metastasize. This agents an comprises anti-galectin 9 antibody as the
 CC active ingredient. The agents and method are for or detecting ability of
 CC cancer to metastasize in cancer cells, which are useful in the diagnosis,
 CC prevention and treatment of cancer. The cancer includes epithelial
 CC malignant tumours (tumourising or non-tumourising) in organs, tissues or
 CC blood. Such cancer can be 1 of the not less than 31 specifically claimed,
 CC e.g. skin cancer (including melanoma), breast cancer, ovarian cancer,
 CC uterine cancer, malignant tumour of the testis, prostate cancer, bladder
 CC cancer, kidney cancer, thyroid cancer, cancer of throat and larynx,
 CC tongue cancer, upper jaw cancer, esophageal cancer, stomach cancer, colon
 CC and rectum cancer, lung and bronchus cancer, liver cancer (including
 CC hepatocarcinoma and intrahepatic biliary cancer), extrahepatic biliary
 CC duct and gall-bladder cancer, pancreatic cancer, leukemia, malignant
 CC lymphoma, liposarcoma and glioma. The cancer cells are particularly
 CC breast cancer cells or melanoma cells. The present sequence represents a
 CC human protein, which is used in the course of the invention
 XX SQ Sequence 355 AA;
 XX SQ 52.4%; Score 163; DB 5; Length 355;
 XX Best Local Similarity 100.0%; Pred. No. 1.3e-155;
 XX Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0
 XX OV 149 TOTVHTYOSAPGMQMFSTPAIIPPMNYPHPAYTPMPFITTIGLYPSKSILLSCTVLPSAQ 208

Db	193	TQTVHTVQSAGQNFSTPAI PPMYMPHAY PMPFTTILGLYPSKSILISGTVLSSAQ	252
QY	209	RPHINLCSGNHIAFHIFNPRDENAVRNTQ.DNSWSEERSILPKMPFVRGOSFSWTLIC	268
Db	253	RPHINLCSGNHIAFHIFNPRDENAVRNTQ.DNSWSEERSILPKMPFVRGOSFSWTLIC	312
QY	269	BAHCKVADGQHIFPEYYHRILRNLTPTINRLLEVGGDQLTHYQT	311
Db	313	BAHCKVADGQHIFPEYYHRILRNLTPTINRLLEVGGDQLTHYQT	355

RESULT 11
ADC53B45

ADC53845 standard; protein; 350 AA.
ADC53845;
18-DEC-2003 (first entry)
Human Galectin 9 protein (long isoform)

XX XX galectin-9; nephritis; glomerular nephritis; antiinflammatory;
 KW glomerular infiltration; apoptosis; human.
 XX XX WO2003016475-A2.
 XX PN XX 27-FEB-2003.
 OS Homo sapiens.
 XX PD XX 14-AUG-2002; 2002WO-US025765.
 PN JP2002322082-A.
 XX PR XX 14-AUG-2001; 2001US-0312147P.
 PD 08-NOV-2002.
 XX PR 01-NOV-2001; 2001US-0346382P.
 PF 26-APR-2001; 2001JP-00129200.
 XX PR 26-APR-2001; 2001JP-00129200.
 XX PR (PROT-) PROTEGENE KK.
 PA PI Woolf C, D'urso D, Beffort K, Costigan M;
 XX XX WPI; 2003-268312/26.
 DR GENBANK; 000182.
 PT Agents for prevention and treatment of nephritis, comprise galectin-1,
 PT Galectin-3, or galectin-9, by inhibition of intraglomerular infiltration
 PT of leukocytes, CD8 positive cells, and induction of apoptosis of CD8
 PT positive cells.
 XX Disclosure; SEQ ID NO 4; 31pp; Japanese.
 XX This invention relates to the use of novel mammal derived galectin-1,
 CC (G1), -3 (G3) and -9 (G9) proteins as effective ingredients for
 prevention and treatment of nephritis. The invention discloses agents for
 CC prevention and treatment of nephritis, particularly glomerular nephritis
 CC and may have antiinflammatory activities. The method of the invention
 CC inhibits glomerular infiltration of leukocytes, CD8 positive cells and
 CC apoptosis of CD8 positive cells. The method and sequences of the
 CC invention may be used for prevention and treatment of nephritis,
 CC particularly glomerular nephritis including inhibition of glomerular
 CC infiltration of leukocytes, CD8 positive cells and apoptosis of CD8
 CC positive cells. The present sequence represents the human galectin 9
 CC protein (long isoform) used in the exemplification of the present
 CC invention.
 XX Sequence 355 AA;
 SQ Query Match 52.4%; Score 163; DB 7; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.3e-155;
 Matches 163; Conservative 0; Mismatches 0; Gaps 0;
 Qy 149 TQTVIHTQSAGQMSTPAIPPMYPHPAYMPFTITLGLYPSKSILLSGTVLPSAQ 208
 Db 193 TQTVIHTQSAGQMSTPAIPPMYPHAYMPFTITLGLYPSKSILLSGTVLPSAQ 252
 Qy 209 RFHINLCSGNHTAFHLNPRDENAVNTQIDNSNGSEERSLPKMPFVRGQSFSWILC 268
 Db 253 RFHINLCSGNHTAFHLNPRDENAVNTQIDNSNGSEERSLPKMPFVRGQSFSWILC 312
 Qy 269 EAHCILKVAVDGQHLEYYHRLNLPTNRLEVGGDQLTHYQT 311
 Db 313 EAHCILKVAVDGQHLEYYHRLNLPTNRLEVGGDQLTHYQT 355
 RESULT 12
 ADE62929 ID ADE62929 standard; protein; 355 AA.
 XX AC ADE62929;
 XX DT 29-JAN-2004 (first entry)
 XX DB Human Protein O00182, SEQ ID NO 8863.
 KW Human; pain; neuronal tissue; gene therapy;
 KW spinal segmental nerve injury; chronic constriction injury; CCI;
 KW spared nerve injury; SNI; Chung.
 XX OS Homo sapiens.

Query Match 52.4%; Score 163; DB 7; Length 355;
 Best Local Similarity 100.0%; Pred. No. 1.3e-155;
 Matches 163; Conservative 0; Mismatches 0; Gaps 0;

Qy 149 TQTVIHTQSAGQMSTPAIPPMYPHPAYMPFTITLGLYPSKSILLSGTVLPSAQ 208
 Db 193 TQTVIHTQSAGQMSTPAIPPMYPHAYMPFTITLGLYPSKSILLSGTVLPSAQ 252
 Qy 209 RFHINLCSGNHTAFHLNPRDENAVNTQIDNSNGSEERSLPKMPFVRGQSFSWILC 268
 Db 253 RFHINLCSGNHTAFHLNPRDENAVNTQIDNSNGSEERSLPKMPFVRGQSFSWILC 312
 Qy 269 EAHCILKVAVDGQHLEYYHRLNLPTNRLEVGGDQLTHYQT 311
 Db 313 EAHCILKVAVDGQHLEYYHRLNLPTNRLEVGGDQLTHYQT 355

RESULT 13
 ADD48101

ID	ADD48101	standard; protein; 355 AA.	Qy	149 TQTVIHTYOSAPGOMESTPAIPPMMPHAYPMPFITITLGGLYPKSILLSCTVLPSEQ 208
XX	ADD48101;		Db	193 TQTVIHTYOSAPGOMESTPAIPPMMPHAYPMPFITITLGGLYPKSILLSCTVLPSEQ 252
AC			Qy	209 RFIINLCSGNHIAFHLPNPFDENAVRVTQIDNSWGSERSLPRKMPFVRQSFSSWILC 268
XX	02-DBC-2004 (revised)	(first entry)	Db	253 RFIINLCSGNHIAFHLPNPFDENAVRVTQIDNSWGSERSLPRKMPFVRQSFSSWILC 312
DT	29-JAN-2004		Qy	269 EAHClikVADGOHLFEYYTHRLRNLPNTINLEVGDDIQLTHVQT 311
XX	Human Protein O00182, SEQ ID NO 13799.		Db	313 EAHClikVADGOHLFEYYTHRLRNLPNTINLEVGDDIQLTHVQT 355
XX	Human; pain; neuronal tissue; gene therapy;			
KW	spinal segmental nerve injury; chronic constriction injury; CCI;			
KW	spared nerve injury; SNI; Chung.			
XX	Homo sapiens.			
OS	Unidentified.			
XX	WO2003016475-A2.		ID	ADG91608 standard; protein; 355 AA.
XX	27-FEB-2003.		XX	ADG91608;
XX	14-AUG-2002; 2002WO-US025765.		AC	
PF	14-AUG-2001; 2001US-0312147P.		XX	
XX	01-NOV-2001; 2001US-0346382P.		DT	11-MAR-2004 (first entry)
PR	26-NOV-2001; 2001US-0333347P.		XX	Human lectin galactoside binding protein (LGAL) #2.
XX	(GEHO) GEN HOSPITAL CORP.		DB	
PA	(FARB) BAYER AG.		KW	Human; lectin galactoside binding protein; LGAL; CHK pathway; cancer; gene therapy.
XX	Woolf C, D'urso D, Befort K, Costigan M;		KW	
XX	WPI; 2003-26812/26.		XX	Homo sapiens.
DR	GENBANK; Q00182.		OS	
XX	New composition comprising two or more isolated polypeptides, useful for preparing a medicament for treating pain in an animal.		XX	XX
PT	Example 1, Page: 1017pp; English.		Key	Location/Qualifiers
XX	PT		16. .147	
PS	PS		FT	/note = Galactose binding lectin domain
XX	Woolf C, D'urso D, Befort K, Costigan M;		FT	226. .335
XX	WPI; 2003-26812/26.		FT	/note = Galactose binding lectin domain
DR	GENBANK; Q00182.		FT	
XX	PT		FT	
XX	PT		PN	US2003165965-A1.
XX	PT		XX	
XX	PT		PF	28-FEB-2003; 2003US-00376133.
XX	PT		XX	
XX	XX		PR	01-MAR-2002; 2002US-0360757P.
CC	The invention discloses a composition comprising two or more isolated rat or human polynucleotides or a polynucleotide which represents a fragment derivative or allelic variation of the nucleic acid sequence. Also claimed are a vector comprising the novel polynucleotide, a host cell comprising the vector, a method for identifying a nucleotide sequence which is differentially regulated in an animal subjected to pain and a kit to perform the method, an array, a method for identifying an agent that increases or decreases the expression of the polynucleotide sequence that is differentially expressed in neuronal tissue of a first animal subjected to pain, a method for identifying a compound which regulates the expression of a polynucleotide sequence which is differentially expressed in an animal subjected to pain, a method for identifying a compound that regulates the activity of one or more of the polynucleotides, a method for producing a pharmaceutical composition, a method for identifying a compound or small molecule that regulates the activity in an animal of one or more of the polypeptides given in the specification, a method for identifying a compound useful in treating pain and a pharmaceutical composition comprising the one or more polypeptides or their antibodies. The polynucleotide or the compound that modulates its activity is useful for preparing a medicament for treating pain (e.g. spinal segmental nerve injury (chung), chronic constriction injury (CCI) and spared nerve injury (SNI)) in an animal (e.g. gene therapy). The sequence presented is a human protein (described in Table 3 of the specification) which is differentially expressed during pain. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic form directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.		XX	The invention relates to lectin galactoside binding proteins (LGALS) and their genes which are identified as modulators of the CHK pathway. It also relates to methods for identifying modulators of the CHK pathway. The method is useful for identifying a candidate CHK pathway modulating agent for preparing a composition for diagnosing or treating diseases e.g. cancer. The sequences of the invention are useful in gene therapy. The present sequence is human LGAL protein. This sequence is used to illustrate the method of the invention.
CC	Sequence 355 AA;		XX	
SQ	Sequence 355 AA;		SQ	Sequence 355 AA;
Query Match	52.4%	Score 163; DB 7; Length 355;	Query Match	52.4%; Score 163; DB 7; Length 355;
Best Local Similarity	100.0%	Pred. No. 1-3e-155;	Best Local Similarity	100.0%; Pred. No. 1-3e-155;
Matches	163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches	163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
				149 TQTVIHTYOSAPGOMESTPAIPPMMPHAYPMPFITITLGGLYPKSILLSCTVLPSEQ 208

Db 193 TQTVIHTVQSPGQMFSTPAIPPMYPHAPMPITTLGGLYPSKSLISGTLPQA 252
 Qy 209 RFHINICSGHIAFHIAFHNPREFDENAVRNTQIDNSIGSEBSLPRKMPFRGOSFVWILC 268
 Db 253 RFHINICSGHIAFHIAFHNPREFDENAVRNTQIDNSIGSEBSLPRKMPFRGOSFVWILC 312
 Qy 269 EAHCILKVAVDGQHLPEYYHRLRNLPTRNLEVGDDIQLTHVQT 311
 Db 313 EAHCILKVAVDGQHLPEYYHRLRNLPTRNLEVGDDIQLTHVQT 355

RESULT 15

AAE13847

ID AAE13847 standard; protein; 378 AA.

XX AAE13847;

XX DT 26-FBB-2002 (First entry)

XX DE Human lung tumour-specific protein 21871.

XX KW Human; lung tumour protein; immunostimulant; cytostatic; gene therapy;
 antisense-therapy; vaccine; immune response; lung cancer; 21871.
 XX OS Homo sapiens.

XX FH Key

Misc-difference 182 .183

FT /note= "Encoded by TRTCC"

XX PN WO2001722295-A2.

XX PD 04-OCT-2001.

XX PP 28-MAR-2001; 2001WO-US009991.

XX PR 29-MAR-2000; 2000US-00538037.

PR 05-JUN-2000; 2000US-00588937.

PR 18-AUG-2000; 2000US-00640878.

PR 22-SEP-2000; 2000US-0234517P.

PR 01-NOV-2000; 2000US-00704512.

PR 14-DEC-2000; 2000US-00738973.

XX PA (CORI-) CORIXA CORP.

XX Reed SG, Lodes MJ, Mohamath R, Secrist H, Benson DR, Indrias CY;
 PI Henderson RA, Flings SP, Algarte PA, Elliot M, Mannion J, Kalos MD;
 XX DR 2001-639201/73.
 N-PSDB; AAD23459.

XX PT New human lung-specific polynucleotides and polypeptides for the
 diagnosis and treatment of disease e.g. lung cancer.
 XX Disclosure; Page 331; 378pp; English.

XX The invention relates to isolated lung tumour-specific proteins and their
 corresponding cDNA molecules. Lung tumour-specific proteins and their
 antigen-presenting cells are useful for stimulating and/or expanding T
 cells specific for a tumour protein, and for inhibiting the development
 of cancer. The invention also relates to a composition useful for
 stimulating an immune response, and for treating cancer. The lung tumour
 specific oligonucleotide is useful in gene therapy and for diagnosis,
 detection and treatment of lung cancer. The present sequence is human
 lung tumour-specific protein

XX Sequence 378 AA;

SQ Query Match 52.4%; Score 163; DB 4; Length 378;

Best Local Similarity 100.0%; Pred. No. 1.4e-155;
 Matches 163; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Search completed: July 13, 2005, 07:50:31
 Job time : 167 secs

Db 149 TQTVIHTVQSPGQMFSTPAIPPMYPHAPMPITTLGGLYPSKSLISGTLPQA 208
 Db 216 TQTVIHTVQSPGQMFSTPAIPPMYPHAPMPITTLGGLYPSKSLISGTLPQA 275
 Qy 209 RFHINICSGHIAFHNPREFDENAVRNTQIDNSIGSEBSLPRKMPFRGOSFVWILC 268
 Db 276 RFHINICSGHIAFHNPREFDENAVRNTQIDNSIGSEBSLPRKMPFRGOSFVWILC 335
 Qy 269 EAHCILKVAVDGQHLPEYYHRLRNLPTRNLEVGDDIQLTHVQT 311
 Db 336 EAHCILKVAVDGQHLPEYYHRLRNLPTRNLEVGDDIQLTHVQT 378

111s rage diank (uspro)

A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-245 <MEH>
A;Cross-references: GB:X78879; NID:9535082; PIDN:CAA55479.1; PID:9535083
C;Superfamily: beta-galactoside-binding lectin
C;Keywords: lectin

Query Match 3.9%; Score 12; DB 2; Length 245;
Best Local Similarity 100.0%; Pred. No. 0.00012; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; DB 158

Qy 55 GNDIAFHNPFRF 66
Db 147 GNDIAFHNPFRF 158

RESULT 3

A54889
IgE-binding protein - rat
C;Species: Rattus norvegicus (Norway rat)
C;Date: 04-Nov-1994 #sequence_revision 04-Nov-1994 #text_change 09-Jul-2004
C;Accession: A54889; AA3148
R;Albrandt, K.; Orida, N.K.; Liu, F.T.; Liu, F.; Kilczycki Jr., A.; Orida, N.K.
Proc. Natl. Acad. Sci. U.S.A. 84, 6859-6863, 1987
A;Title: An IgE-binding protein with a distinctive repetitive sequence and homology with
A;Accession number: A54889; MUID:88016189; PMID:2958848
A;Accession: A54889
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-262 <ALB>
A;Cross-references: UNIPROT: P08699; GB:J02962; NID:9203173; PIDN:AAA40828.1; PID:9203174
R;Liu, F.T.; Albrandt, K.; Mendez, E.; Kilczycki Jr., A.; Orida, N.K.
Proc. Natl. Acad. Sci. U.S.A. 82, 4100-4104, 1985
A;Title: Identification of an IgE-binding Protein by molecular cloning.
A;Accession number: A23148; MUID:85216641; PMID:3858867
A;Accession: A23148
A;Molecule type: mRNA
A;Residues: 125-262 <LUU>
A;Cross-references: GB:M13697; NID:9204727; PIDN:AAA41378.1; PID:9204728
C;Superfamily: beta-galactoside-binding lectin
C;Keywords: lectin; phosphoprotein

Query Match 3.9%; Score 12; DB 2; Length 262;
Best Local Similarity 100.0%; Pred. No. 0.00018; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0; DB 175

Qy 55 GNDIAFHNPFRF 66
Db 164 GNDIAFHNPFRF 175

RESULT 4

A46631
Iactose-binding lectin L-36 - rat
N;Alternate names: galactin-4
C;Species: Rattus norvegicus (Norway rat)
C;Date: 21-Sep-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C;Accession: A46631; S83096
R;Poda, Y.; Harrmann, J.; Gitt, M.A.; Turck, C.W.; Burlingsame, A.L.; Barondes, S.H.; Leff J. Biol. Chem. 268, 5939-5939, 1993
A;Title: Soluble lactose-binding lectin from rat intestine with two different carbohydrate
A;Accession number: A46631; MUID:93194902; PMID:8449956
A;Accession: A46631
A;Status: preliminary
A;Molecule type: nucleic acid
A;Residues: 1-324 <ODA>
A;Cross-references: UNIPROT:P38552; GB:MT3553; NID:9294571; PIDN:AAA41505.1; PID:9294572
A;Experimental source: intestine backbone (NCBIN:128409, NCBIPI:128410)
A;Note: sequence extracted from NCBI backbone (NCBIN:128409, NCBIPI:128410)
R;Tardy, F.; Deviller, P.; Louisot, P.; Martin, A.
PES Lett. 359, 169-172, 1995
A;Title: Purification and characterization of the N-terminal domain of galectin-4 from
A;Reference number: S63096; MUID:9517227; PMID:7867792

Query Match 3.2%; Score 10; DB 2; Length 324;
Best Local Similarity 100.0%; Pred. No. 0.029; Mismatches 0; Indels 0; Gaps 0;

Qy 57 DIAFHNPFRF 66
Db 59 DIAFHNPFRF 68

RESULT 5

S08576
lectin - mouse (fragment)
C;Species: Mus musculus (house mouse)
C;Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 09-Jul-2004
C;Accession: S08576
R;Raz, A.; Carmi, P.; Pazerini, G.
Cancer Res. 48, 645-659, 1988
A;Title: Expression of two different endogenous galactoside-binding lectins sharing sequ
A;Reference number: S07162; MUID:8808093; PMID:3335026
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-139 <RAZ>
A;Cross-references: UNIPROT:Q61357
C;Superfamily: beta-galactoside-binding lectin

Query Match 2.6%; Score 8; DB 2; Length 139;
Best Local Similarity 100.0%; Pred. No. 1.8; Mismatches 0; Indels 0; Gaps 0;

Qy 59 AFFHNPRF 66
Db 72 AFFHNPRF 79

RESULT 6

JC4300
galactin-3 - rabbit
C;Species: Oryctolagus cuniculus (domestic rabbit)
C;Date: 16-Nov-1995 #sequence_revision 08-Feb-1996 #text_change 09-Jul-2004
C;Accession: JC4300
R;Gaudin, J.-C.; Monsigny, M.; Legrand, A.
Gene 163, 249-252, 1995
A;Title: Cloning of the cDNA encoding rabbit galactin-3.
A;Reference number: JC4300; MUID:96011642; PMID:7590275
A;Accession: JC4300
A;Molecule type: mRNA
A;Residues: 1-242 <GAU>
A;Cross-references: UNIPROT:P47845; GB:U06470; NID:9606794; PIDN: AAC48491.1; PID:9606795
A;Experimental source: vascular smooth muscle cells
A;Note: The authors translated the codon RTC for residue 155 as Leu
C;Comment: This protein has the functions on cell adhesion and proliferation. It is a su
A;Gene: Igale3
C;Superfamily: beta-galactoside-binding lectin
C;Keywords: muscle

Query Match 2.6%; Score 8; DB 2; Length 242;
Best Local Similarity 100.0%; Pred. No. 2.9; Mismatches 0; Indels 0; Gaps 0;

Qy 59 AFFHNPRF 66
Db 148 AFFHNPRF 155

RESULT 7

A35620
galactin 3 - human
N;Alternate names: CBP '35; epithelial-specific lectin 35; galactoside-binding lectin L-2
C;Species: Homo sapiens (man)
C;Accession: 12-Oct-1990 #sequence revision 12-Oct-1990 #text_change 09-Jul-2004
R;Oda, Y.; Lettier, H.; Sakakura, Y.; Kasai, K.; Barondes, S.H.
Gene 99, 279-283, 1991
A;Title: Human breast carcinoma cDNA encoding a galactoside-binding lectin homologous to
A;Reference number: JQ0916; MUID:9121671; PMID:2261464
A;Accession: A35820
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-250 <ROB>
A;Cross-references: UNIPROT:P17931; GB:M57710; PIDN:AAA35607.1; PID:g179531
R;Lotz, M.M.; Andrews, J.T.; C.W.; Korzelius, C.A.; Lee, E.C.; Steele Jr., G.D.; Clarke, A.
Proc. Natl. Acad. Sci. U.S.A. 90, 3466-3470, 1993
A;Title: Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its
A;Reference number: A47473; MUID:9323418; PMID:7682704
A;Accession: A47473
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-63, 'P', 65-97, 'T', 99-250 <LOT>
A;Cross-references: GB:S559012; NID:g299601; PIDN:AAB26229.1; PID:g299602
A;Experimental source: normal colonic mucosa, colon carcinoma, cell line clone A
A;Note: sequence extracted from NCBI backbone (NCBIN:129699, NCBIPI:129692)
R;Cheravil, B.J.; Chaitovitz, S.; Wong, C.; Pillai, S.
Proc. Natl. Acad. Sci. U.S.A. 87, 7324-7328, 1990
A;Title: Molecular cloning of a human macrophage lectin specific for galactose.
A;Reference number: A356071; MUID:90384999; PMID:2402511
A;Accession: A36071
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-32, 'Q', '34', 'L', '37', 'RGFLSNGL', '46', 'RAGT', '51, 'R', '53-63, 'P', '65-87, 89-250 <CHE>
A;Cross-references: GB:M35365; NID:91196441
A;Note: the sequence is revised in GenBank entry HUMMAC2, release 113.0. PIDN:AAA88086.1
R;Raz, A.; Carmi, P.; Raz, T.; Hogan, V.; Mohamed, A.; Wolman, S.R.
Cancer Res. 51, 2173-2178, 1991
A;Title: Molecular cloning and chromosomal mapping of a human galactoside-binding protein
A;Reference number: A49800; MUID:91183475; PMID:2009335
A;Accession: A49800
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: mRNA
A;Residues: 1-32, 'Q', '34', 'LPGASYPGAPGTPGLSNTAPPATMHEVLLTRSTCWLSLRQ', '86-104, 'A', '106, 'M
A;Cross-references: GB:M64303; NID:9413862
A;Note: this translation is not annotated in GenBank entry HUMGALBIN, release 113.0
C;Genetics:
A;Gene: GDB:LGALS3; MAC-2; LGALS2
A;Cross-references: GDB:127515; OMIM:137033
A;Map position: 1P13-1P13
C;Superfamily: beta-galactoside-binding lectin
C;Keywords: lectin; nucleus; phosphoprotein

Query Match 2.6%; Score 8; DB 2; Length 250;
Best Local Similarity 100.0%; Pred. No. 3; Indels 0; Gaps 0;

Qy 59 AFHENPRF 66
Db 156 AFHENPRF 163

N;Alternate names: carbohydrate-binding protein 35; IgE-binding protein; lectin L-34; Ma
C;Species: Mus musculus (house mouse)
C;Date: 28-Aug-1989 #sequence revision 10-Feb-1995 #text_change 09-Jul-2004
R;Cheravil, B.J.; Weiner, S.J.; Pillai, S.
J. Exp. Med. 170, 1959-1972, 1989
A;Title: The Mac-2 antigen is a galactose-specific lectin that binds IgE.
A;Reference number: S08537; MUID:90063462; PMID:2584931
A;Accession: S08537
A;Status: nucleic acid sequence not shown; translation not shown
A;Molecule type: mRNA
A;Residues: 1-264 <CHE>
A;Cross-references: UNIPROT:P16110; EMBL:X16834; PIDN:952986; PID:952987
A;Note: this sequence was submitted to the EMBL Data Library, Oct-1989
R;Jia, S.; Wang, J.L.
J. Biol. Chem. 263, 6005-6011, 1988
A;Title: Carbohydrate binding protein 35. Complementary DNA sequence reveals homology with
A;Reference number: A28651; MUID:88198129; PMID:3360772
A;Accession: A28651
A;Molecule type: mRNA
A;Residues: R', 3-264 <JIA>
A;Cross-references: EMBL:J03723
R;Rez, A.; Paperini, G.; Carni, P.
Cancer Res. 49, 3499-3493, 1989
A;Title: Identification of the metastasis-associated, galactoside-binding lectin as a ch
A;Reference number: A37385; MUID:89273058; PMID:2525069
A;Accession: A37385
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-3, 'T', 5-91, 'ST', '94-109, 'SAP', '113-264 <RAZ>
A;Cross-references: GB:X16074; PIDN:CA34206.1; PID:952851
A;Note: authors translated the codon GAA for residue 221 as Ala, GAC for residue 221 as
R;Woo, H.J.; Shaw, L.M.; Messier, J.M.; Mercurio, A.M.
J. Biol. Chem. 265, 7097-7098, 1990
A;Title: The major non-integron laminin binding protein of macrophages is identical to c
A;Reference number: A35185; MUID:90236991; PMID:2332426
A;Accession: A35185
A;Molecule type: protein
A;Residues: 159-162,166-175,214-226 <WOO>
C;Superfamily: betagalactoside-binding lectin
C;Keywords: lectin; phosphoprotein

Query Match 2.6%; Score 8; DB 2; Length 264;
Best Local Similarity 100.0%; Pred. No. 3 2;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 59 AFHENPRF 66
Db 170 AFHENPRF 177

RESULT 9
A45983
lactose-binding lectin Mac-2 - mouse
C;Species: Mus musculus (house mouse)
C;Accession: A45983
R;Rosenberg, I.M.; Iyer, R.; Cheravil, B.; Chiodino, C.; Pillai, S.
J. Biol. Chem. 268, 12393-12400, 1993
A;Title: Structure of the murine Mac-2 gene. Splice variants encode proteins lacking fur
A;Reference number: A45983; MUID:93286070; PMID:8509379
A;Accession: A45983
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-264 <ROS>
A;Cross-references: UNIPROT:Q8C253; GB:L08649
C;Genetics:
A;Introns: 6/3; 128/3; 158/2; 209/2; 213/3
C;Superfamily: betagalactoside-binding lectin

Query Match 2.6%; Score 8; DB 2; Length 264;
Best Local Similarity 100.0%; Pred. No. 3 2;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 59 AFHENPWF 66
 Db 170 AFHENPWF 177

RESULT 10
 A4688
 Lactose-binding lectin L-29 - dog
 C;Species: Canis lupus familiaris (dog)
 C;Date: 02-Jun-1995 #sequence_revision 02-Jun-1995 #text_change 24-Nov-1999
 C;Accession: A49688
 R;Herzmann, J.; Turck, C.W.; Atchison, R.E.; Huflejt, M.B.; Poulter, L.; Gitt, M.A.; Bur
 J. Biol. Chem. 268, 26704-26711, 1993
 A;Title: Primary structure of the soluble lactose binding lectin L-29 from rat and dog a
 agnase.
 A;Reference number: A49688; MUID:94075368; PMID:8253805
 A;Accession: A49688
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-294 <HER>
 A;Cross-references: GB:L23429
 C;Keywords: beta-galactoside-binding lectin
 C;Keywords: acetylated amino end
 P;1/Modified site: acetylated amino end (Ala) #status experimental

Query Match 2.6% Score 8; DB 2; Length 294;
 Best Local Similarity 100.0%; Pred. No. 3.5%;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 59 AFHENPWF 66
 Db 200 AFHENPWF 207

RESULT 11
 A55975
 Galectin-8 - rat
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 23-Mar-1995 #sequence_revision 05-Apr-1995 #text_change 09-Jul-2004
 R;Hadari, Y.R.; Paz, K.; Dekel, R.; Nestrovic, T.; Accili, D.; Zick, Y.
 J. Biol. Chem. 270, 3447-3453, 1995
 A;Title: Galectin-8. A new rat lectin, related to galectin-4.
 A;Reference number: A55975; MUID:95155445; PMID:7852031
 A;Accession: A55975
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-316 <HAD>
 A;Cross-references: UNIPROT:Q62665; GB:U09924; PID:9717031; MUID:AAA66359.1; PMID:9717032
 C;Superfamily: lactose-binding lectin L-36

Query Match 2.6% Score 8; DB 2; Length 316;
 Best Local Similarity 100.0%; Pred. No. 3.7%;
 Matches 8; Conservative 0; Mismatches 0; Gaps 0;

QY 59 AFHENPWF 66
 Db 62 AFHENPWF 69

RESULT 12
 JC6147
 prostate carcinoma tumor antigen 1 - human
 C;Species: Homo sapiens (man)
 C;Date: 02-Sep-1997 #sequence_revision 05-Sep-1997 #text_change 29-Sep-1999
 C;Accession: JC6147
 R;Su, Z.Z.; Lin, J.; Shen, R.; Fisher, P.E.; Goldstein, N.I.; Fisher, P.B.
 Proc. Natl. Acad. Sci. U.S.A. 93, 7252-7257, 1996
 A;Title: Surface-epitope masking and expression cloning identifies the human prostate ca
 A;Reference number: JCC6147; MUID:8692978
 A;Accession: JC6147
 A;Molecule type: mRNA

A;Residues: 1-317 <SUA>
 A;Cross-references: GB:L78132; PID:G1932711; PID:AB51605.1; PID:G1932712
 C;Comment: This protein is a therapeutic reagent for intervention in pervasive and fatal
 tein is a member of the Glectin family.
 C;Superfamily: lactose-binding lectin L-36
 C;Keywords: tumor

Query Match 2.6% Score 8; DB 2; Length 317;
 Best Local Similarity 100.0%; Pred. No. 3.8%;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 59 AFHENPWF 66
 Db 63 AFHENPWF 70

RESULT 13
 A55664
 lectin L-36 - pig
 C;Species: Sus scrofa domestica (domestic pig)
 C;Date: 11-Aug-1995 #sequence_revision 11-Aug-1995 #text_change 09-Jul-2004
 C;Accession: A55664
 R;Chiu, M.L.; Parry, D.A.D.; Feldman, S.R.; Klapper, D.G.; O'Keefe, E.J.
 J. Biol. Chem. 269, 31770-31776, 1994
 A;Title: An adherens junction protein is a member of the family of lactose-binding lectin
 A;Reference number: A55664; MUID:95081129; PMID:7989350
 A;Accession: A55664
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-323 <CH1>
 A;Cross-references: UNIPROT:Q29058; GB:X79303; PID:9623345; PMID:GAA55884.1; PID:G623346
 C;Superfamily: lactose-binding lectin L-36

Query Match 2.6% Score 8; DB 2; Length 323;
 Best Local Similarity 100.0%; Pred. No. 3.8%;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 59 AFHENPWF 66
 Db 61 AFHENPWF 68

RESULT 14
 AD2580
 two component sensor kinase Atu0027 [Imported] - Agrobacterium tumefaciens (strain C58,)
 C;Species: Agrobacterium tumefaciens
 C;Date: 11-Jan-2002 #sequence_revision 11-Jan-2002 #text_change 09-Jul-2004
 C;Accession: AD2580
 R;Wood, D.W.; Setubal, J.C.; Kaul, R.; Monk, D.; Chen, L.; Wood, G.E.; Chen, Y.; Woo, L.
 erage, G.; Gillet, W.; Grant, C.; Guenther, D.; Kutyavin, T.; Levy, R.; Li, M.; McClellan,
 i, Karp, P.; Romero, P.; Zhang, S.
 Science 294, 2317-2323, 2001
 A;Authors: Yoo, H.; Tao, Y.; Biddle, P.; Jung, M.; Krespan, W.; Perry, M.; Gordon-Kamm, I
 ster, E.W.
 A;Title: The Genome of the Natural Genetic Engineer Agrobacterium tumefaciens C58.
 A;Reference number: AB2577; MUID:21608550; PMID:11743193
 A;Accession: AD2580
 A;Status: preliminary
 A;Molecule type: DNA
 A;Residues: 1-881 <KUR>
 A;Cross-references: UNIPROT:Q8UJAI; GB:AE008688; PID:AAL41058.1; PMID:917738345; GSPDB:GN
 C;Genetics:
 A;Gene: Atu0027
 A;Map position: circular chromosome

Query Match 2.6% Score 8; DB 2; Length 881;
 Best Local Similarity 100.0%; Pred. No. 9.7%;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 ILLSGTVAL 204
 Db 69 ILLSGTVAL 76

RESULT 15

C97362 protein sensor protein (AF042096) [Imported] - Agrobacterium tumefaciens (strain C58, Ce
C;Species: Agrobacterium tumefaciens
C;Date: 30-Sep-2001 #sequence_revision 30-Sep-2001 #text_change 09-Jul-2004
C;Accession: C97362
R;Goodner, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Qurollo, B.; Goldman, A.; Liu, F.; Wollam, C.; Allinger, M.; Doughty, D.; Scott, C.; Lappas, C.; Markelz, B.; Science 294, 2323-2328, 2001
A;Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tum
A;Reference number: A97359; PMID:21608551;
A;Accession: C97362
A;Status: Preliminary
A;Molecule type: DNA
A;Residues: 1-881 <KUR>
A;Cross-references: UNIPROT:Q8UJAI; PIDN:AAK85852.1; PID:g15154889; GSFPDB:G
C;Genetics:
A;Gene: AGR_C_44
A;Map position: circular chromosome

Query Match 2.6% Score 8; DB 2; Length 881;

Best Local Similarity 100.0%; Pred. No. 9.7;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 ILLSGTIVL 204

Db 69 ILLSGTIVL 76

Search completed: July 13, 2005, 08:02:31
Job time : 42 secs

This Page Blank (uspto)